Amidation of unactivated ester derivatives mediated by trifluoroethanol by McPherson, Christopher G. et al.
McPherson, Christopher G. and Caldwell, Nicola and Jamieson, Craig 
and Simpson, Iain and Watson, Allan J. B. (2017) Amidation of 
unactivated ester derivatives mediated by trifluoroethanol. Organic and 
Biomolecular Chemistry. ISSN 1477-0520 , 
http://dx.doi.org/10.1039/C7OB00593H
This version is available at https://strathprints.strath.ac.uk/60404/
Strathprints is  designed  to  allow  users  to  access  the  research  output  of  the  University  of 
Strathclyde. Unless otherwise explicitly stated on the manuscript, Copyright © and Moral Rights 
for the papers on this site are retained by the individual authors and/or other copyright owners. 
Please check the manuscript for details of any other licences that may have been applied. You 
may  not  engage  in  further  distribution  of  the  material  for  any  profitmaking  activities  or  any 
commercial gain. You may freely distribute both the url (https://strathprints.strath.ac.uk/) and the 
content of this paper for research or private study, educational, or not-for-profit purposes without 
prior permission or charge. 
Any correspondence concerning this service should be sent to the Strathprints administrator: 
strathprints@strath.ac.uk
The Strathprints institutional repository (https://strathprints.strath.ac.uk) is a digital archive of University of Strathclyde research 
outputs. It has been developed to disseminate open access research outputs, expose data about those outputs, and enable the 
management and persistent access to Strathclyde's intellectual output.
Journal Name  
ARTICLE 
This journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 1  
Please do not adjust margins 
Please do not adjust margins 
a. Department of Pure and Applied Chemistry, University of Strathclyde, 295 
Cathedral Street, Glasgow, G1 1XL, UK. 
b. AstraZeneca, Oncology Innovative Medicines, Darwin Building, Unit 310 
Cambridge Science Park, Milton Road, Cambridge, CB4 0WG, UK.  
Electronic Supplementary Information (ESI) available: experimental procedures 
and spectroscopic data for all compounds]. See DOI: 10.1039/x0xx00000x 
Received 00th January 20xx, 
Accepted 00th January 20xx 
DOI: 10.1039/x0xx00000x 
www.rsc.org/ 
Amidation of Unactivated Ester Derivatives Mediated by 
Trifluoroethanol  
Christopher G. McPherson,a Nicola Caldwell,a Craig Jamieson,*a Iain Simpsonb and Allan J. B. 
Watsona 
A catalytic amidation protocol mediated by 2,2,2-trifluoroethanol has been developed, facilitating the condensation of 
unactivated esters and amines, furnishing both secondary and tertiary amides.  The complete scope and limitations of the 
method are described, along with modified conditions for challenging substrates such as acyclic secondary amines and 
chiral esters with retention of chiral integrity. 
Introduction 
The amide functional group is extensively encountered within 
nature and medicinal chemistry, where it is commonly found 
in peptide bonds in proteins and small-molecule drugs, 
respectively.1,2 Approximately a quarter of registered drugs are 
found to contain an amide bond,3 thereby making amide bond 
formation one of the most frequently executed 
transformations within the pharmaceutical industry.4,5 
However, established methods for the synthesis of amides 
from carboxylic acids have a number of drawbacks, particularly 
with regard to atom economy and sustainability, which 
ultimately limit their effective application.6 In recent years, 
several catalytic amidation methods have emerged seeking to 
improve the atom economy of this process, and thus 
minimising environmental impact.7-13 
 
When considering the use of esters as coupling partners, 
stoichiometric approaches allowing the direct conversion of 
esters to amides have also been developed, overcoming the 
protracted reaction times and high temperatures associated 
with aminolysis.14,15 In recent years, catalytic approaches 
enabling the aminolysis of ester derivatives have been 
reported.16-22 However, despite the benefits of these catalytic 
approaches, a number of limitations hinder their application. 
In some cases only a limited substrate scope have beeen 
demonstrated with respect to the acylating species, whereas 
other approaches require the use of transition or rare earth 
metals, raising potential issues associated with both toxicity  
 
 
 
and sustainability.    
 
Within our own laboratories, a programme focused on 
catalytic amide bond formation has been developed in recent 
years,23-26 with a view to addressing some of the outstanding 
issues associated with this important transformation.  
 
In a recent report, we aimed to determine if an exogenous 
alcohol-derived additive could be employed to facilitate an 
initial transesterification,  forming an active ester intermediate 
(1, Scheme 1) in situ, and ultimately enabling the direct 
reaction of simple ester derivatives with amines.27 Through a 
combination of reaction screening, where a range of additives, 
bases and solvents were evaluated, and the application of 
Design of Experiments (DoE) optimisation methods,28 it was 
possible to develop a sustainable, inexpensive and 
unprotracted procedure for the synthesis of amides from 
unactivated ester derivatives and primary or cyclic secondary 
amines using a catalytic quantity (20 mol%) of 2,2,2-
trifluoroethanol (TFE) as an additive (Scheme 1).  
 
 
 
 
 
 
 
 
Scheme 1. TFE-mediated catalytic amidation procedure. 
In the current study, we present the full scope and limitations 
of the complete process. We demonstrate the importance of 
the choice of base on the outcome of the reaction, as well as 
reporting further extension of the methodology in order to 
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allow the incorporation of secondary acyclic amines, 
previously intractable in the progenitor process. In addition to 
this, we demonstrate an improved method for the preparation 
of amide substrates based on enantiopure starting materials 
with good retention of stereoconfiguration.   
Results and Discussion 
In our initial study, to investigate the general utility of the 
methodology, a range of ester and amine starting materials 
were assessed for their applicability in this reaction manifold 
(Scheme 2). In our preliminary communication, a broad range 
of amides were able to be prepared under the optimum 
conditions developed.27 Several aryl esters, substituted with 
both electron-withdrawing and electron-donating groups were 
successfully coupled with benzylamine, furnishing the 
corresponding amides (2-6) in good to excellent yields. 
However, electron rich aryl esters (6) were noted to be 
comparatively less competent coupling partners. 
 
Aliphatic esters were also tolerated (7-11), including two 
amino acid-derived substrates (11 & 12).  However, significant 
erosion of enantiopurity was unfortunately observed when 
ƵƐŝŶŐĂŶɲ-chiral ester, affording 11 (ee = 8% as determined by 
chiral HPLC), which represented a limitation of the first 
generation method at this stage. Esters containing heterocyclic 
motifs (12-15) were also found to be proficient coupling 
partners with pyridine- (12), pyrimidine- (13), and thiophene- 
(14) derived species furnishing good to excellent yields of the 
respective amide derivatives.  
 
Variation of the amine coupling partner from benzylamine 
allowed further exemplification of the process. Aliphatic 
amines could be successfully applied alongside heterocyclic 
(15) and aliphatic (16) esters. The successful coupling of 
piperidine (17, 18) and piperazine (19) derivatives extended 
the substrate scope, highlighting the applicability of the 
approach to cyclic secondary amines. In order to demonstrate 
the successful application of our methodology to a medicinally 
relevant compound, the experimental Ampakine Farampator 
(20), currently in Phase II trials for ADHD,29 was prepared in a 
good yield of 60% in one step. Despite the general utility of the 
method with the exemplars shown above, tertiary amides 
prepared from acyclic secondary amines such as N-
methylbenzylamine (21) and dibenzylamine (22) could not be 
prepared using this methodology, highlighting a second 
limitation of the initially developed method. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2. Representative scope of first generation process reported previously.27 
Isolated yields shown. a 8% ee as determined by chiral HPLC. b Synthesised from the 
corresponding ethyl ester starting material. 
In an effort to extend the utility of the process to 
accommodate previously problematic substrates such as acylic 
secondary amines and chiral ester derivatives, we first sought 
to establish the role of pKa of the conjugate acid associated 
with the base used. When developing our first generation 
process, it was noted that the pKa values of both K3PO4 and 
TFE are extremely similar (12.3 and 12.5, respectively). In 
order to investigate whether this alignment of base and 
additive pKa is a prerequisite for the reaction to proceed 
efficiently, a selection of bases, representing a broader range 
of pKa values than initially studied, were screened using a 
model system (Table 1). Initial attempts focused on retaining 
the potassium counterion (Table 1, Entries 1-8). From this it 
could be noted that K3PO4 (Entry 6) was the optimal choice 
with a 78% conversion obtained, fully consistent with our 
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previous observations. Potassium tert-butoxide (Entry 8) also 
furnished the desired amide product but in a comparatively 
lower conversion of 47%. The phosphate species of the base 
was then retained and the role of the metal counterion was 
next examined. (Table 1, Entries 9-13). The use of Mg3PO4 
(Entry 12) resulted in the only measurable conversion of 16%, 
with the other counterions proving unsuccessful for reaction 
progression. Cs2CO3 (Entry 14) also led to poor conversion, 
indicating that potassium was the preferred counterion. 
 
A range of organic bases were then explored (Entries 15-19), 
with all but DBU (Entry 18, 61%) proceeding with either no or 
minimal conversion to the amide product. From consideration 
of this extended base study, it can be concluded that those 
bases with a pKa in line with that of TFE (K3PO4 and DBU) 
perform considerably better in the reaction manifold than 
bases with a pKa either greater or less than 12. The exception 
to this is KOtBu which, although furnishes the amide in 
moderate yield, is still less effective than the original base of 
choice.  Clearly, the choice of counterion is also important with 
other phosphate salts proving ineffective in the reaction. This 
observation may be attributable to the solubility of the TFE 
adduct in the reaction milieu.  
 
Table 1. Further investigation into the nature of the base species.  
 
 
 
 
Entry Base pKa Conversion (%) 
1 KTFA 0 1 
2 KH2PO4 2 1 
3 KOAc 6 1 
4 K2HPO4 7 1 
5 K2CO3 10 2 
6 K3PO4 12 78 
7 KOH 16 5 
8 KOtBu 18 47 
9 Ca3PO4 13 1 
10 Cs3PO4 13 1 
11 Li3PO4 13 0 
12 Mg3PO4 13 16 
13 Na3PO4 13 1 
14 Cs2CO3 10 11 
15 NMO 7 13 
16 DABCO 9 4 
17 Et3N 11 1 
18 DBU 12 61 
19 BEMP 19 8 
 
With further understanding into the choice of base used, 
attention then turned to addressing the limitations identified 
above. As discussed previously, the incompatibility of acyclic 
secondary amines with the previously optimised conditions to 
form tertiary amides represents a major gap in the scope of 
method. We proposed that altering the additive, base and 
solvent may overcome this problem. To this end, a model 
system was again examined, and the effects of altering the 
additive, base and solvent analysed via HPLC, the results of 
which are presented in Table 2.  
In the first instance, the model amidation was repeated using 
the conditions optimised for our progenitor process, resulting 
in only 1% conversion to the desired amide (Table 2, Entry 1). 
Moderate formation of the desired amide, however, was 
noted when using K3PO4 in conjunction with cyclopentylmethyl 
ether (CPME), 1,4-Dioxane and 2-MeTHF (Table 2, Entry 2-4). 
Consistent with the extended base screen discussed above, no 
other base was seen to promote the reaction. One exception 
to this is the use of KOtBu (Table 2, Entries 5-7) where the 
desired amide could be formed in conversions of up to 96%. 
However, when the reaction was performed in the absence of 
the TFE additive, substantial direct aminolysis was observed 
(Table 2, Entry 7). This is consistent with earlier reports of 
using KOtBu to promote amidation of ester derivatives, we 
believe that the KOtBu is facilitating the reaction via radical-
based process.31,32  
Table 2. Initial tertiary amide optimisation 
 
 
 
 
aReaction performed in the absence of TFE. 
 
With modest conversion to the desired amide observed, 
further optimisation was undertaken. At this point in the 
study, the ester species used in the model reaction was altered 
to methyl 4-(trifluoromethyl)benzoate, as the inherent 
electron-withdrawing characteristic of which was anticipated 
to  make the desired amidation reaction more amenable. 
Despite examining a more activated substrate, the amidation 
reaction was still found to not proceed when run in THF (Table 
3, Entry 1). Interestingly, altering the order of addition of the 
reaction, allowing a 30 minute window for formation of the 
active ester intermediate before addition of the amine, 
resulted in the desired amidation proceeding in 70% 
conversion (Table 3, Entry 2). This was then subsequently 
applied to the amidation of methyl benzoate where a 
significant increase in obtained conversion was again observed 
(Table 3, Entry 3). Based on these results, we reason that 
concomitant addition of the reactants result in a preferential 
formation of a quaternary ammonium salt between 
trifluoroethanol and the amine substrate, precluding 
Entry Base Solvent  Conversion (%) 
1 K3PO4 THF 1 
2 K3PO4 CPME 37 
3 K3PO4 1,4-Dioxane 12 
4 K3PO4 2-MeTHF 43 
5 KOtBu CPME 96 
6 KOtBu THF 56 
7a KOtBu CPME 58 
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formation of the target amide due to sequestration of the TFE 
catalyst in the insoluble base matrix. 
 
With the aim of further optimising this observed conversion, 
the temperature of the reaction was increased, with the 
solvent selected accordingly (Table 3, Entries 4-6). Pleasingly, 
this resulted in a 93% isolated yield of the desired amide when 
carrying out the reaction in dioxane (Table 3, Entry 5). 
Importantly, the corresponding control reactions resulted in 
no amide product (Table 3, Entries 7-9), confirming that the 
reaction does not proceed via direct aminolysis but instead 
requires formation of the TFE-derived active ester species.     
 
Table 3. Tertiary amide optimisation with increased temperature. 
 
 
 
 
 
Entry Solvent Temperature 
(qC) 
Conversion 
 (%) 
1 THF 90 0 
2a THF 90 70 
3a,b THF 90 62 
4a CPME 125 77c 
5a 1,4-Dioxane 125 93c 
6a 2-MeTHF 100 72c 
7a,d 1,4-Dioxane 125 0c 
8a,e 1,4-Dioxane 125 0c 
9a,f 1,4-Dioxane 125 0c 
a30 min preformation of active ester at reaction temperature. bMethyl benzoate 
used as ester substrate. cIsolated yield. dPerformed in the absence of K3PO4.                    
ePerformed in the absence of TFE. fPerformed in the absence of both K3PO4 and 
TFE. 
With optimum conditions allowing the coupling of acyclic 
secondary amines now established, we first sought to 
investigate the scope of the ester component of the reaction 
(Scheme 3). Pleasingly, several aryl esters, containing both 
electron-withdrawing and electron-donating groups were 
successfully coupled with N-methylbenzylamine, furnishing the 
corresponding amides (23-30) in good to excellent yields. 
Exceptions to this include the coupling of methyl 4-
aminobenzoate (27), and ring systems bearing ortho 
substitution (e.g. 30). Heteroaryl esters were also tolerated 
within the reaction in moderate yields (31 and 32). Alkyl esters 
(33 and 34) furnished the corresponding amide products in 
excellent yields when evaluated using this second generation 
method.  
 
 
 
 
 
 
Scheme 3. Investigating the scope of the ester component. aSynthesised from the 
corresponding ethyl ester starting material.  
Having investigated the scope of the ester component in 
conjunction with a model acyclic secondary amine, attention 
was turned to variation of the amine coupling partner (Scheme 
4). This was somewhat more limited in scope, as for example, 
it was found that increasing the size of the substituent from N-
methylbenzylamine to the corresponding ethyl, isopropyl, 
butyl and dibenzyl- derivatives (35-38) was not tolerated, 
presumably due to steric hindrance. Returning to methylated 
derivatives, substitution on the aromatic ring in the form of an 
o-methoxy was tolerated in modest yield (39). 
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Scheme 4. Substrate scope of the acyclic secondary amine component 
 
Pleasingly, homologation of the amine was tolerated in 
moderate to good yield (40 and 41). Unfortunately, aniline 
derivatives, such as 42, were not competent substrates under 
these new conditions, which can be ascribed to their 
inherently lower nucleophilicity. A range of heteroaryl derived 
amines (43-45) were successful coupling partners with 
moderate to good yields of the corresponding amides 
obtained. By contrast, alkyl amines (46, 47 and 48) were in 
general not compatible with the reaction manifold. In the case 
of amines such as 46 and 47 we propose this is attributable to 
the volatility of the amine starting material under the high 
temperature required for the reaction to proceed. However, as 
expected, the electron rich amine 49 was found to undergo 
amidation efficiently, forming the expected product in 99% 
yield. 
 
Despite the success in developing reaction conditions that 
were suitable for a number of acyclic secondary amine 
substrates, from consideration of the substrate scope above, it 
can be noted that a number of exemplars could only be 
isolated in sub-optimal yields. In order to address this, we 
reasoned that increasing the quantity of the trifluoroethanol 
additive from a catalytic amount (20 mol%) to a full equivalent 
may lead to increased yields. Accordingly, a subset of the 
amide products previously examined were re-evaluated to 
investigate this proposal (Scheme 5). 
 
 
 
 
 
 
 
 
 
Scheme 5. Application of stoichiometric TFE additive. a) yield obtained using 20 mol% 
TFE. 
From the chosen subset, it was apparent that the use of a full 
equivalent of TFE does, indeed, in most cases increase the 
yield obtained. The para fluoro substrate (50) could be 
obtained in good yield of 58% compared to the previous 18%. 
A range of heteroaryl esters (51-54) demonstrate the same 
marked improvement, and in the case of the furan (32) and 
thiophene (54) derivatives, almost full conversion of the ester 
to the amide is obtained. For the glycine derived alkyl ester 55, 
a more modest increase in yield to 38% is observed. Pleasingly, 
the pyrrolidinone derived ester 56, which was not a competent 
substrate when using catalytic quantities of TFE, is now a 
viable with a good yield of 62%.  
 
Unfortunately, the ethyl-derived amine 35 remained 
incompatible with these conditions, supporting our earlier 
observations that more sterically crowded secondary amines 
do not undergo the desired amidation. However, the pyridine 
derived amine 57 reflects the increased yields seen when 
varying the ester substrate, and affords the corresponding 
tertiary amide in 70%. In a similar fashion, the thiophene 
derived methylamine (44) also exhibits a significant 
improvement in yield, with 92% of the amide product isolated, 
compared to the previous 19%. Finally, an alkyl amine 
previously studied was re-evaluated using a full equivalent of 
TFE. Amide 58, previously obtained in 12% yield, could now be 
isolated in a yield 65%.  
 
Despite having compromised the catalytic nature of the 
reactions for these more demanding substrates, this 
stoichiometric approach compares favourably with other 
established methods of amide coupling, especially given the 
low cost of TFE33 as an additive. Accordingly, application of 
stoichiometric quantities of TFE is a viable approach for 
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substrates that are not compatible with the catalytic reaction 
manifold. 
 
Having successfully adapted the first generation method to 
enable the condensation of acyclic secondary amines, 
attention was turned to the remaining limitation of our 
progenitor process. As discussed above, the amidation of 
benzylamine and Boc-Phe-OMe to the corresponding amide 
(11) resulted essentially in complete epimerisation. Altering 
the additive used from trifluoroethanol to 4-
(trifluoromethyl)phenol was found to minimise the extent of 
racemisation, affording the amide in a comparable yield of 
38% with an ee of 65%. Encouraged by this, we conducted a 
more extensive screen of potential bases and additives in 
order to identify further enhancements in both the yield and 
corresponding enantiomeric excess of the amide product. 
Accordingly, the coupling of Boc-Phe-OMe with benzylamine 
mediated by 4-(trifluoromethyl)phenol was selected as the 
model reaction, with the effect of varying the base initially 
investigated (Table 4). 
 
Table 4. Effect of varying the base on the yield and ee obtained. 
 
 
 
 
 
Entry Base pKa Yield (%) ee 
1 KTFA 0 46 93 
2 KH2PO4 2 62 87 
3 KOAc 6 55 92 
4 NMO 7 36 92 
5 K2HPO4 7 48 92 
6 DABCO 9 40 85 
7 K2CO3 10 46 75 
8 Cs2CO3 10 34 40 
9 DBU 12 69 16 
 
From consideration of the data in Table 4, a clear trend can be 
discerned between the strength of base and the extent of 
racemisation (Figure 2). The use of KTFA (Table 4, Entry 1), 
with a pKa of 0, results in minimal racemisation, whereas, if a 
base with a pKa of greater 10 is used (Table 4, Entries 7-9), high 
levels of racemisation are observed. Based on this, the base 
offering the best combination of isolated yield relative to 
product ee was deemed to be KOAc and, as such, was retained 
for use in the following additive screen (Table 5). 
 
 
 
 
 
Figure 1. Effect of the pKa of the base compared to the ee of the obtained product. 
 
Table 5. Effect of varying the additive on the yield and ee obtained. 
 
Entry Additive pKa Yield (%) ee 
1 Picoline n-oxide - 28 87 
2 HOCt 2 54 91 
3 HOAt 3 32 89 
4 HOBt 5 47 91 
5 Oxyma 5 50 93 
6 NHS 8 58 79 
7 4-CF3C6H4OH 9 55 92 
8 HFIP 9 35 89 
9 TFE 12 31 89 
 
It can be noted from Table 5 that the nature of the additive 
has little effect on the ee obtained, with only N-
hydroxysuccinimide (Table 5, Entry 6) leading to a product with 
an ee less than 87 % (Figure 3). The use of HOCt34 (Table 5, 
Entry 2) and 4-(trifluoromethyl)phenol (Table 5, Entry 7) led to 
comparative yields and ee of the desired product, with 4-
(trifluoromethyl)phenol selected as the optimum additive due 
to a marginally superior yield to ee balance. 
 
In order to elucidate at which point epimerisation occurred in 
the reaction, Boc-Phe-OMe and the corresponding amide 
product (11) were individually subjected to the reaction 
conditions in the absence of both 4-(trifluoromethyl)phenol 
and benzylamine (Table 6).  
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Table 6. Epimerisation Study 
 
 
 
 
 
 
 
 
Entry Substrate Initial 
ee 
ee upon reaction 
completion  
1 Boc-Phe-OMe 100 100 
2 11 92 92 
 
As shown in Table 6, after being subjected to the reaction 
conditions, both Boc-Phe-OMe and 11 showed no degradation 
in enantiopurity. It can, therefore, be inferred that the 
observed level of racemisation in the reaction occurs at the 
point of nucleophilic attack of the amine to the activated ester 
species. 
 
Having developed optimum conditions providing excellent 
levels of stereoretention, a range of D-chiral esters were 
prosecuted to validate the generality of the transformation 
(Scheme 6).  
 
Scheme 6. Substrate scope of enantiopure esters.  
Pleasingly, good to excellent levels of stereoretention were 
observed across the range of D-chiral esters subjected to the 
optimised conditions. Amino acid derived amides (59-61) were 
successfully synthesised in moderate yield. Incorporation of a 
hydroxyl group in the alpha position was also tolerated 
without significant deterioration in the observed enantiomeric 
excess, with the corresponding D-hydroxy amides obtained in 
moderate to good yields (62-64). A dioxolane containing ester 
was successfully coupled, furnishing the desired amide in 
excellent yield and stereoretention (65). Ibuprofen was also 
successfully utilised as a substrate, however the corresponding 
amide was obtained in poor yield but with good retention of 
enantiopurity.   
Conclusions 
In summary, we have successfully developed a novel 
organocatalysed approach to amide bond formation, from 
readily available unactivated ester starting starting materials. 
From initial conditions allowing the coupling of primary and 
cyclic secondary amines, further tuning of reaction conditions 
allowed the process to be optimised for secondary amines 
which had previously proven intractable. A range of tertiary 
amides were then successfully synthesised, with the process 
tolerant to various functionalities. The original conditions were 
also successfully adapted via alteration of the additive and 
base from TFE/K3PO4 to 4-(trifluoromethyl)phenol/KOAC, 
which successfully incorporated the application of alpha chiral 
esters to our amidation protocol. Corresponding chiral amides 
were synthesised accordingly with good to excellent retention 
of chiral integrity observed. 
Experimental Section 
General Methods. All reagents and solvents were used as obtained 
unless otherwise stated. Purification was carried out according to 
standard laboratory methods.35 BEMP was purified by vacuum 
distillation from CaH2 and stored in a septum-sealed oven-dried 
flask over previously activated 4 Å molecular sieves and purged with 
and stored under nitrogen. Reactions were carried out under 
Schlenk conditions using oven-dried glassware, which was 
evacuated and purged with N2 before use. Thin layer 
chromatography was carried out using aluminum-backed silica 
plates which were analysed under 254 nm UV light or developed 
using potassium permanganate solution. Flash chromatography 
was carried out using ZEOprep 60 HYD 40-63 µm silica gel. 1H 
NMR spectra were recorded at 400 or 500 MHz, and 13C NMR 
spectra were recorded at 101 or 126 MHz. Chemical shifts are 
reported in ppm, and coupling constants are reported in hertz with 
CDCl3 referenced at 7.26 (1H) and 77.16 ppm (13C), and DMSO 
referenced at 2.50 (1H) and 39.52 ppm (13C). Variable temperature 
NMR experiments were performed at 400 MHz (1H) and 126 MHz 
(13C) at 298 or 333K.  Mass spectrometry data was generated using 
a TOF analyzer. Optical rotations were measured at 589 nm, with 
concentrations reported in grams per 100 mL. Conversions were 
determined by HPLC using caffeine as an internal standard. Chiral 
HPLC data was obtained on an Agilent 1260 Infinity HPLC using a 
Chiralpak IA column. The data for products 2  ? 20 were reported in 
our earlier communication.27 
General Method for for Chiral Secondary Amide Substrate Scope 
To an oven-dried, purged and sealed Schlenk tube containing 4-
(trifluoromethyl)phenol (46 mg, 0.28 mmol, 0.2 equiv.), KOAc (139 
mg, 1.42 mmol, 1 equiv.), ester (1.42 mmol, 1 equiv.) and THF (700 
ʅ> ? ǁĂƐ added benzylamine (155 µL, 1.42 mmol, 1 equiv.). The 
reaction mixture was heated at 90 °C for 22 h then diluted with 
EtOAc (10 mL), washed with brine (3 x 10 mL), dried over Na2SO4, 
and concentrated to a residue in vacuo which was purified by silica 
gel chromatography (MeOH/CH2Cl2 or Acetone/Pet. Ether 40  ? 60 
qC). 
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General Method for Tertiary Amide Ester Substrate Scope 
 To an oven-dried, purged and sealed Schlenk tube containing 
trifluoroethanol (20 µL, 0.28 mmol, 0.2 equiv.), K3PO4 (301 mg, 1.42 
mmol, 1 equiv.) and 1,4-ŝŽǆĂŶĞ  ? ? ? ? ʅ> ? ǁĂƐ ĂĚĚĞĚ ĞƐƚĞƌ   ? ? ? ? ?
mmol, 1 equiv.) and the reaction heated at 125 qC for 30 min. N-
methylbenzylamine (183 µL, 1.42 mmol, 1 equiv.) was then added 
and the reaction mixture was heated at 125 qC for a further 22 h. 
Reaction was then diluted with EtOAc (10 mL), washed with brine (3 
x 10 mL), dried over Na2SO4, and concentrated to a residue in vacuo 
which was purified by silica gel chromatography (MeOH/CH2Cl2). 
 
N-benzyl-N-methylbenzamide (23).36 Purified by silica gel 
chromatography (1% MeOH/CH2Cl2), affording the title compound 
as a yellow oil (226 mg, 71%): ʆmax (neat) 3060, 3029, 2921, 1629, 
1398, 1264, 1068, 698 cm-1; 1H NMR (400 MHz, 333 K, DMSO-d6): 
GH  7.45  ? 7.42 (m, 5H), 7.39 -7.36 (m, 2H), 7.29 (t, J = 7.2 Hz, 3H), 
4.60 (s, 2H), 2.86 (s, 3H); 13C NMR (101 MHz, CDCl3): GC 172.4, 171.7, 
137.2, 136.7, 136.4, 129.7, 128.9, 128.5, 128.3, 127.7, 127.1, 126.9, 
55.3, 50.9, 37.1, 33.3 (mixture of rotamers); HRMS (ESI) m/z: 
[M+H]+ calcd for C15H16NO 226.1226, found 226.1224. 
N-benzyl-N-methyl-4-(trifluoromethyl)benzamide (24).37  Purified by 
silica gel chromatography (1% MeOH/CH2Cl2), affording the title 
compound as a yellow oil (386 mg, 93%): ʆmax (neat) 3066, 3032, 
2926, 1634, 1407, 1325, 1167, 1109, 1072, 852, 700 cm-1; 1H NMR 
(500 MHz, 333 K, DMSO-d6): GH  7.79 (d, J = 7.5 Hz, 2H), 7.66 (d, J = 
7.7 Hz, 2H), 7.39  ? 7.28 (m, 5H), 4.69  ? 4.44 (m, 2H), 2.85 (s, 3H); 13C 
NMR (126 MHz, 333 K, DMSO-d6): GC 169.0, 140.3, 136.8, 129.5 (q, 
2JCF  = 32.0 Hz), 128.4, 127.3, 127.0, 125.1 (q, 3JCF = 3.6 Hz), 123.7 (q, 
1JCF = 272.4 Hz), 53.8, 49.8, 36.4, 32.5 (mixture of rotamers); HRMS 
(ESI) m/z: [M+H]+ calcd for C16H15F3NO 294.1100, found 294.1096. 
N-benzyl-4-cyano-N-methylbenzamide (25).38  Purified by silica gel 
chromatography (1% MeOH/CH2Cl2), affording the title compound 
as a yellow oil (153 mg, 43%): ʆmax (neat) 3060, 3030, 2924, 2230, 
1632, 1402, 1264, 1070, 850, 700 cm-1; 1H NMR (400 MHz, 333 K, 
DMSO-d6): GH 7.89 (d, J = 7.9 Hz, 2H), 7.62 (d, J = 7.9 Hz, 2H), 7.39  ? 
7.28 (m, 5H), 4.66 (s, 2H), 2.85 (s, 3H); 13C NMR (101 MHz, CDCl3): GC 
170.4, 169.7, 140.8, 140.7, 136.6, 136.0, 132.5, 129.2, 129.0, 128.4, 
128.1, 127.9, 127.8, 127.6, 126.6, 118.2, 113.6, 55.1, 51.0. 36.9, 
33.5 (mixture of rotamers); HRMS (ESI) m/z: [M+H]+ calcd for 
C16H15N2O 251.1179, found 251.1178. 
N-benzyl-4-chloro-N-methylbenzamide (26).37 Purified by silica gel 
chromatography (1% MeOH/CH2Cl2), affording the title compound 
as a yellow solid (229 mg, 62%): ʆmax (neat) 3055, 3030, 2913, 1632, 
1409, 1087, 1074, 1016, 843, 739, 698 cm-1; 1H NMR (400 MHz, 333 
K, DMSO-d6): GH  7.50  ? 7.45 (m, 4H), 7.39  ? 7.35 (m, 2H), 7.31  ? 
7.27 (m, 3H), 4.59 (s, 2H), 2.86 (s, 3H); 13C NMR (101 MHz, CDCl3): GC 
171.3, 170.7, 136.9, 136.5, 135.9, 134.7, 128.9, 128.7, 128.5, 128.4, 
127.8, 126.7, 55.3, 51.1, 37.1, 33.5 (mixture of rotamers); HRMS 
(ESI) m/z: [M+H]+ calcd for C15H15ClNO 260.0837, found 260.0831. 
 N-benzyl-4-methoxy-N-methylbenzamide (28).39 Purified by silica 
gel chromatography (1% MeOH/CH2Cl2), affording the title 
compound as a yellow oil (258 mg, 71%): ʆmax (neat) 2958, 2919, 
2839, 1625, 1608, 1396, 1249, 1174, 1029, 841, 700 cm-1; 1H NMR 
(400 MHz, 333 K, DMSO-d6): GH 7.43 - 7.35 (m, 4H), 7.30  ? 7.26 (m, 
3H), 6.99  ? 6.96 (m, 2H), 4.60 (s, 2H), 3.80 (s, 3H), 2.88 (s, 3H); 13C 
NMR (101 MHz, CDCl3): GC 171.8, 160.8, 137.2, 129.1, 128.9, 128.4, 
127.6, 126.9, 113.8, 55.4, 51.2, 37.3, 33.6 (mixture of rotamers); 
HRMS (ESI) m/z: [M+H]+ calcd for C16H18NO2 256.1332, found 
256.1325. 
N-benzyl-3-methoxy-N-methylbenzamide (29).38 Purified by silica gel 
chromatography (1% MeOH/CH2Cl2), affording the title compound 
as a yellow oil (338 mg, 93%): ʆmax (neat) 3062, 3029, 3004, 2935, 
2835, 1630, 1580, 1398, 1269, 1042, 750, 698 cm-1; 1H NMR (400 
MHz, 333 K, DMSO-d6): GH 7.39  ? 7.27 (m, 6H), 7.01  ? 6.95 (m, 3H), 
4.58 (s, 2H), 3.76 (s, 3H), 2.86 (s, 3H); 13C NMR (101 MHz, CDCl3): GC 
159.7, 129.7, 128.9, 128.3, 127.7, 126.8, 119.2, 119.0, 115.9, 115.5, 
112.6, 112.1, 55.4, 50.9, 37.1, 33.4 (mixture of rotamers); HRMS 
(ESI) m/z: [M+H]+ calcd for C16H18NO2 256.1332, found 256.1328. 
N-benzyl-2-methoxy-N-methylbenzamide (30). Purified by silica gel 
chromatography (1% MeOH/CH2Cl2), affording the title compound 
as a yellow oil (78 mg, 21%): ʆmax (neat) 3062, 3029, 3004, 2922, 
2837, 1629, 1601, 1400, 1247, 1024, 754, 700 cm-1; 1H NMR (400 
MHz, 333 K, DMSO-d6): GH 7.42  ? 6.95 (m, 9H), 4.69 (s, 1H), 4.30 (s, 
1H), 3.83 (s, 2H), 3.78 (s, 1H), 2.88 (s, 1H), 2.68 (s, 2H) (mixture of 
rotamers); 13C NMR (101 MHz, 333 K, DMSO-d6): GC 168.2, 154.7, 
137.1, 136.7, 129.9, 128.2, 127.4, 127.1, 127.0, 126.8, 126.7, 126.2, 
120.5, 120.3, 111.4, 55.4, 55.2, 53.3, 49.1, 35.1, 31.6 (mixture of 
rotamers); HRMS (ESI) m/z: [M+H]+ calcd for C16H18NO2 256.1332, 
found 256.1330. 
N-benzyl-N-methylnicotinamide (31). Purified by silica gel 
chromatography (2% MeOH/CH2Cl2), affording the title compound 
as a yellow oil (166 mg, 52%): ʆmax (neat) 3026, 2919, 1627, 1400, 
1074, 1026, 734, 699 cm-1; 1H NMR (400 MHz, 333 K, DMSO-d6): GH 
8.64 (d, J = 5.4 Hz, 2H), 7.86 (d, J = 7.3 Hz, 1H), 7.47  ? 7.28 (m, 6H), 
4.62 (s, 2H), 2.90 (s, 3H); 13C NMR (101 MHz, CDCl3): GC 169.8, 169.1, 
150.9, 148.1, 147.9, 136.7, 136.1, 135.1, 134.8, 132.2, 129.1, 129.0, 
128.4, 127.9, 126.7, 123.5, 55.3, 51.1, 37.1, 33.7 (mixture of 
rotamers); HRMS (ESI) m/z: [M+H]+ calcd for C14H15N2O 227.1179, 
found 227.1173. 
N-benzyl-N-methyl-2-phenylacetamide (33).37 Purified by silica gel 
chromatography (1% MeOH/CH2Cl2), affording the title compound 
as a yellow oil ( 336 mg, 99%): ʆmax (neat) 3062, 3029, 2921, 1640, 
1400, 1109, 731, 698 cm-1; 1H NMR (400 MHz, 333 K, DMSO-d6): GH 
7.31  ? 7.20 (m, 10H), 4.62 (s, 1H), 4.53 (s, 1H), 3.77 (s, 2H), 2.94 (s, 
2H), 2.82 (s, 1H) (mixture of rotamers); 13C NMR (101 MHz, 333 K, 
DMSO-d6): GC 170.2, 137.5, 135.5, 128.7, 128.1, 127.9, 127.2, 126.7, 
126.0, 52.6, 49.9, 34.8; HRMS (ESI) m/z: [M+H]+ calcd for C16H18NO 
240.1383, found 240.1382. 
N-benzyl-N-methyl-2-(pyridin-2-yl)acetamide (34). Purified by silica 
gel chromatography (2% MeOH/CH2Cl2), affording the title 
compound as an orange oil (293 mg, 87%): ʆmax (neat) 3060, 3029, 
3008, 2924, 1642, 1435, 1400, 1111, 756, 733, 700 cm-1; 1H NMR 
(400 MHz, 333 K, DMSO-d6): GH 8.49 (s, 1H) 7.73 (t, J = 6.8 Hz, 1H), 
7.32 (d, J = 7.8 Hz, 3H), 7.24 (d, J = 7.0 Hz, 3H), 4.69 (s, 1H), 4.54 (s, 
1H), 3.94 (s, 1H), 3.91 (s, 1H), 2.99 (s, 2H), 2.82 (s, 1H) (mixture of 
rotamers); 13C NMR (101 MHz, 333 K, DMSO-d6): GC 169.5, 156.0, 
148.6, 136.0, 128.3, 128.1, 127.2, 126.9, 126.6, 126.4, 123.5, 121.4, 
52.7, 49.9, 42.6, 35.0, 33.1 (mixture of rotamers); HRMS (ESI) m/z: 
[M+H]+ calcd for C15H17N2O 241.1335, found 241.1335. 
 
General Method for Tertiary Amide Amine Substrate Scope 
To an oven-dried, purged and sealed Schlenk tube containing 
trifluoroethanol (20 µL, 0.28 mmol, 0.2 equiv.), K3PO4 (301 mg, 1.42 
mmol, 1 equiv.) and 1,4-ŝŽǆĂŶĞ  ? ? ? ? ʅ> ? ǁĂƐ ĂĚĚĞĚ ŵĞƚŚǇů
benzoate  (178 µL, 1.42 mmol, 1 equiv.) and the reaction heated at 
125 qC for 30 min. Amine (1.42 mmol, 1 equiv.) was then added and 
the reaction mixture was heated at 125 qC for a further 22 h. 
Reaction was then diluted with EtOAc (10 mL), washed with brine (3 
x 10 mL), dried over Na2SO4, and concentrated to a residue in vacuo 
which was purified by silica gel chromatography (MeOH/CH2Cl2). 
 
N-(2-methoxybenzyl)-N-methylbenzamide (39). Purified by silica gel 
chromatography (1% MeOH/CH2Cl2), affording the title compound 
as a yellow solid (113 mg, 31%): ʆmax (neat) 3017, 2924, 2842, 1629, 
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1241, 1024, 756, 728 cm-1; 1H NMR (500 MHz, 333 K, DMSO-d6): GH 
7.42 (s, 5H), 7.30  ? 7.26 (m, 1H), 7.18 (s, 1H), 7.01  ? 6.96 (m, 2H), 
4.54 (s, 2H), 3.76 (s, 3H), 2.86 (s, 3H); 13C NMR (101 MHz, CDCl3): GC 
172.7, 171.7, 136.8, 136.6, 129.6, 129.3, 128.8, 128.4, 127.8, 127.0, 
120.8, 120.7, 110.4, 55.5,55.2, 50.7, 45.5, 37.5, 33.4 (mixture of 
rotamers); HRMS (ESI) m/z: [M+H]+ calcd for C16H18NO2 256.1332, 
found 256.1332. 
N-methyl-N-phenethylbenzamide (40).40 Purified by silica gel 
chromatography (1% MeOH/CH2Cl2), affording the title compound 
as a yellow oil (271 mg, 80%): ʆmax (neat) 3060, 3027, 2928, 1629, 
1400, 1070, 700 cm-1; 1H NMR (400 MHz, 333 K, DMSO-d6): GH 7.43 
 ? 7.38 (m, 3H), 7.28 - 7.19 (m, 7H), 3.54 (s, 2H), 2.86 (s, 5H); 13C 
NMR (101 MHz, CDCl3): GC 172.3, 171.4, 139.2, 138.0, 136.7, 129.5, 
129.3, 129.0, 128.9, 128.7, 128.4, 127.0, 126.6, 53.1, 49.5, 38.4, 
34.9, 33.6, 33.2 (mixture of rotamers); HRMS (ESI) m/z: [M+H]+ 
calcd for C16H18NO 240.1383, found 240.1379. 
N-methyl-N-(3-phenylpropyl)benzamide (41). Purified by silica gel 
chromatography (1% MeOH/CH2Cl2), affording the title compound 
as an orange oil (121 mg, 34%): ʆmax (neat) 3060, 3027, 2930, 2861, 
1629, 1400, 1072, 700 cm-1; 1H NMR (400 MHz, 333 K, DMSO-d6): 
GH 7.42  ? 7.37 (m, 3H), 7.35  ? 7.33 (m, 2H), 7.27  ? 7.23 (m, 2H), 7.18 
 ? 7.14 (m, 2H), 3.35 (s, 2H), 2.92 (s, 3H), 2.54 (s, 4H), 1.87 (m, 2H); 
13C NMR (101 MHz, CDCl3): GC  172.1, 171.5, 141.8, 140.9, 136.8, 
129.5, 128.6, 128.5, 128.2, 127.0, 126.7, 126.2, 51.0, 47.4, 37.6, 
33.4, 32.9, 32.8, 29.9, 28.8 (mixture of rotamers); HRMS (ESI) m/z: 
[M+H]+ calcd for C17H20NO 254.1539, found 254.1533. 
N-methyl-N-(pyridin-2-ylmethyl)benzamide (43).41  Purified by silica 
gel chromatography (1% MeOH/CH2Cl2), affording the title 
compound as a yellow oil (190 mg, 59%): ʆmax (neat) 3058, 3010, 
2926, 1629, 1398, 1072, 702 cm-1; 1H NMR (400 MHz, 333 K, DMSO-
d6): GH 8.57  ? 8.55 (m, 1H), 7.79 (td, J = 7.7, 1.8 Hz, 1H), 7.44 (s, 5H), 
7.31  ? 7.28 (m, 2H), 4.66 (s, 2H), 2.95 (s, 3H); 13C NMR (101 MHz, 
CDCl3): GC 172.7, 171.7, 157.3, 156.9, 150.0, 149.4, 137.0, 130.2, 
129.8, 128.5, 127.2, 127.0, 122.6, 122.3, 121.0, 57.1, 53.1, 38.0, 
33.8 (mixture of rotamers); HRMS (ESI) m/z: [M+H]+ calcd for 
C14H15N2O 227.1179, found 227.1175. 
N-(furan-2-ylmethyl)-N-methylbenzamide (45). Purified by silica gel 
chromatography (1% MeOH/CH2Cl2), affording the title compound 
as a brown oil (183 mg, 60%): ʆmax (neat) 3116, 3060, 2922, 1630, 
1400, 1068, 1014, 700 cm-1; 1H NMR (400 MHz, 333 K, DMSO-d6): 
GH 7.60 (dd, J = 1.8, 0.8 Hz, 1H), 7.47  ? 7.40 (m, 5H), 6.43 (dd, J = 3.2, 
1.9 Hz), 6.35 (s, 1H), 4.54 (s, 2H), 2.89 (s, 3H); 13C NMR (101 MHz, 
CDCl3) GC 172.2, 171.5, 150.9, 150.3, 142.8, 142.5, 136.2, 129.3, 
128.5, 127.2, 110.5, 108.8, 108.6, 48.5, 43.8, 37.3, 33.0 (mixture of 
rotamers); HRMS (ESI) m/z: [M+H]+ calcd for C13H14NO2 216.1019, 
found 216.1016. 
N-(cyclohexylmethyl)-N-methylbenzamide (48). Purified by silica gel 
chromatography (1% MeOH/CH2Cl2), affording the title compound 
as a yellow oil (83 mg, 25%): ʆmax (neat) 2921, 2850, 1629, 1448, 
1402, 1288, 1070, 700 cm-1; 1H NMR (400 MHz, 333 K, DMSO-d6): 
GH 7.44  ? 7.40 (m, 3H), 7.35  ? 7.32 (m, 2H), 3.23 (s, 2H), 2.90 (s, 3H), 
1.70  ? 1.55 (m, 7H), 1.22  ? 1.17 (m, 4H); 13C NMR (126 MHz, CDCl3): 
GC 172.5, 171.8, 167.7, 137.2, 137.1, 135.1, 131.4, 129.4, 129.2, 
128.7, 128.5, 127.2, 127.0, 57.7, 53.7, 46.4, 38.5, 38.2, 36.5, 36.0, 
33.3, 31.1, 30.9, 30.6, 26.6, 26.5, 26.4, 26.1, 26.0, 25.9 (mixture of 
rotamers); HRMS (ESI) m/z: [M+H]+ calcd for C15H22NO 232.1696, 
found 232.1693.                                                                                                           
N-(2,2-dimethoxyethyl)-N-methylbenzamide (49). Purified by silica 
gel chromatography (1% MeOH/CH2Cl2), affording the title 
compound as a yellow oil (314 mg, 99%): ʆmax (neat) 2935, 2835, 
1632, 1400, 1126, 1072, 1027, 702 cm-1; 1H NMR (500 MHz, 333 K, 
DMSO-d6): GH  7.44  ? 7.43 (m, 3H), 7.38 7.36 (m, 2H), 4.56 (s, 1H), 
3.44 (s, 2H), 3.30 (s, 6H), 2.96 (s, 3H); 13C NMR (126 MHz, CDCl3): GC  
172.6, 171.8, 136.5, 129.7, 128.5, 127.1, 103.5, 103.1, 54.8, 53.2, 
50.0, 39.6, 34.5 (mixture of rotamers); HRMS (ESI) m/z: [M+H]+ 
calcd for C12H18NO3 224.1281, Found 224.1281.   
General Method for Tertiary Amide Substrate Scope Using a Full 
Equivalent of TFE 
To an oven-dried, purged and sealed Schlenk tube containing 
trifluoroethanol (100 µL, 1.42 mmol, 1 equiv.), K3PO4 (301 mg, 1.42 
mmol, 1 equiv.) and 1,4-ŝŽǆĂŶĞ  ? ? ? ? ʅ> ? ǁĂƐ ĂĚĚĞĚ ĞƐƚĞƌ   ? ? ? ? ?
mmol, 1 equiv.) and the reaction heated at 125 qC for 30 min. 
Amine (1.42 mmol, 1 equiv.) was then added and the reaction 
mixture was heated at 125 qC for a further 22 h. Reaction was then 
diluted with EtOAc (10 mL), washed with brine (3 x 10 mL), dried 
over Na2SO4, and concentrated to a residue in vacuo which was 
purified by silica gel chromatography (MeOH/CH2Cl2). 
 
N-benzyl-N-methylfuran-2-carboxamide (32).37 Purified by silica gel 
chromatography (1% MeOH/CH2Cl2), affording the title compound 
as an orange oil (304 mg, 99%): ʆmax (neat) 3112, 3062, 3030, 2922, 
1621, 1493, 1400, 1070, 746, 700 cm-1; 1H NMR (500 MHz, 333 K, 
DMSO-d6): GH 7.80 (s, 1H), 7.36 (t, J = 7.5 Hz, 2H), 7.28 (dd, J = 10.1, 
7.7 Hz, 3H), 7.00 (s, 1H), 6.60 (dd, J = 3.1, 1.6 Hz, 1H), 4.72 (s, 2H), 
3.06 (s, 3H); 13C NMR (126 MHz, CDCl3): GC  160.6, 148.1, 144.1, 
137.0, 128.8, 128.3, 127.6, 127.1, 116.6, 111.4, 54.3, 52.0, 35.9, 
34.4 (mixture of rotamers); HRMS (ESI) m/z: [M+H]+ calcd for 
C13H14NO2 216.1019, found 216.1015. 
N-methyl-N-(thiophen-2-ylmethyl)benzamide (44). Purified by silica 
gel chromatography (1% MeOH/CH2Cl2), affording the title 
compound as a yellow oil (304 mg, 92%): ʆmax (neat) 3062, 2924, 
1629, 1398, 1068, 700 cm-1; 1H NMR (400 MHz, 333 K, DMSO-d6): 
GH 7.47  ? 7.40 (m, 6H), 7.04 (s, 1H), 7.00 (dd, J = 5.1, 3.4 Hz, 1H)  
4.74 (s, 2H), 2.90 (s, 3H); 13C NMR (101 MHz, CDCl3): GC 174.1, 139.8, 
136.2, 128.6, 127.1, 126.1, 125.7, 50.6, 45.9, 37.0, 32.9 (mixture of 
rotamers); HRMS (ESI) m/z: [M+H]+ calcd for C13H14NOS 232.0791, 
found 232.0787. 
N-benzyl-4-fluoro-N-methylbenzamide (50).39 Purified by silica gel 
chromatography (1% MeOH/CH2Cl2), affording the title compound 
as a yellow oil (200 mg, 58%): ʆmax (neat) 3064, 3029, 2922, 1630, 
1604, 1400, 1225, 1068, 847, 700 cm-1; 1H NMR (400 MHz, 333 K, 
DMSO-d6): GH 7.53 - 7.49 (m, 2H), 7.39  ? 7.35 (m, 2H), 7.31  ? 7.22 
(m, 5H), 4.60 (s, 2H), 2.87 (s, 3H) ; 13C NMR (101 MHz, CDCl3): GC 
170.7, 163.5 (d, 1JCF = 249.5 Hz), 137.0, 136.7, 132.4, 129.4, 129.0, 
128.4, 127.8, 126.7, 115.6 (d, 2JCF = 21.8 Hz), 55.4, 51.1, 37.2, 33.6; 
HRMS (ESI) m/z: [M+H]+ calcd for C15H15FNO 244.1132, found 
244.1127.             
N-benzyl-N,6-dimethylnicotinamide (51). Purified by silica gel 
chromatography (2% MeOH/CH2Cl2), affording the title compound 
as a yellow oil (181 mg, 53%): ʆmax (neat) 3030, 2922, 1629, 1599, 
1402, 1074, 754, 700 cm-1; 1H NMR (500 MHz, 333 K, DMSO-d6): GH 
8.53 (s, 1H), 7.76 (d, J = 7.3 Hz, 1H), 7.38 (t, J = 7.5 Hz, 2H), 7.32  ? 
7.29 (m, 4H), 4.62 (s, 2H), 2.90 (s, 3H), 2.51 (s, 3H); 13C NMR (101 
MHz, CDCl3): GC 170.1, 169.4, 160.1, 147.6, 147.3, 136.7, 136.2, 
135.5, 135.2, 129.2, 129.0, 128.9, 128.3, 127.8, 126.6 123.0, 55.3, 
51.1, 37.1, 33.6, 24.5 (mixture of rotamers); HRMS (ESI) m/z: 
[M+H]+ calcd for C15H17N2O 241.1335, found 241.1330. 
N-benzyl-N-methylpyrazine-2-carboxamide (52). Purified by silica 
gel chromatography (1% MeOH/CH2Cl2), affording the title 
compound as a yellow oil (130 mg, 40%): ʆmax (neat) 3058, 3025, 
2924, 1632, 1085, 1019, 701 cm-1; 1H NMR (400 MHz, 333 K, DMSO-
d6): GH 8.87 (d, J = 13.8 Hz, 1H), 8.72 (d, J = 9.9 Hz, 1H), 8.66 (d, J = 
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14.0 Hz, 1H), 7.37  ? 7.26 (m, 5H), 4.73 (s, 1H), 4.60 (s, 1H), 2.96 (s, 
1H), 2.93 (s, 2H) (mixture of rotamers); 13C NMR (101 MHz, CDCl3): 
GC 167.1, 166.8, 150.0, 149.9, 145.7, 145.6, 145.4, 142.7 (2), 136.5, 
136.4, 128.9, 128.4, 128.0, 127.8, 127.5, 54.8, 51.6, 36.6, 33.8 
(mixture of rotamers); HRMS (ESI) m/z: [M+H]+ calcd for C13H12N3O 
226.0986, found 226.0976. 
N-benzyl-N-methyl-1H-pyrrole-2-carboxamide (53).42 Purified by 
silica gel chromatography (1% MeOH/CH2Cl2), affording the title 
compound as an orange solid (218 mg, 71%): ʆmax (neat) 3231, 
1589, 1400, 1134, 788, 730, 721, 691 cm-1; 1H NMR (400 MHz, 333 
K, DMSO-d6): GH 11.31 (s, 1H), 7.38  ? 7.26 (m, 5H), 6.90 (td, J = 2.7, 
1.4 Hz, 1H), 6.48 (s, 1H), 6.11 (dt, J = 3.6, 2.5 Hz, 1H) 4.75 (s, 2H), 
3.11 (s, 3H); 13C NMR (101 MHz, CDCl3): GC 163.0, 137.3, 128.9, 
127.5, 121.5, 112.8, 109.8, 52.5, 36.2 (mixture of rotamers); HRMS 
(ESI) m/z: [M+H]+ calcd for C13H15N2O 215.1179, Found 215.1179.   
N-benzyl-N-methylthiophene-2-carboxamide (54). Purified by silica 
gel chromatography (1% MeOH/CH2Cl2), affording the title 
compound as a yellow oil (313 mg, 95%): ʆmax (neat) 3086, 3029, 
2921, 1608, 1396, 1029, 700 cm-1; 1H NMR (400 MHz, 333 K, DMSO-
d6): GH 7.74 (dd, J = 5.0, 1.1 Hz, 1H), 7.44 (d, J = 3.0 Hz, 1H), 7.41  ? 
7.36 (m, 2H), 7.31  ? 7.27 (m, 3H), 7.10 (dd, J = 5.0, 3.7 Hz, 1H), 4.73 
(s, 2H), 3.08 (s, 3H); 13C NMR (101 MHz, CDCl3): GC 164.9, 137.9, 
136.9, 129.2, 129.0, 127.7, 126.9, 53.5, 35.7; HRMS (ESI) m/z: 
[M+H]+ calcd for C13H14NOS 232.0791, found 232.0786                                                      
tert-butyl (2-(benzyl(methyl)amino)-2-oxoethyl)carbamate (55).43 
Purified by silica gel chromatography (1% MeOH/CH2Cl2), affording 
the title compound as a yellow oil (152 mg, 38%): ʆmax (neat) 3406, 
2978, 2934, 1711, 1653, 1368, 1163, 1052, 702 cm-1; 1H NMR (500 
MHz, 333 K, DMSO-d6): GH 7.33  ? 7.22 (m, 5H), 4.52 (s, 2H), 3.85 (d, 
J = 4.9 Hz, 2H), 3.68 (d, J = 6.2 Hz, 1H), 2.90  ? 2.78 (m, 3H), 1.39 (s, 
9H) (mixture of rotamers); 13C NMR (126 MHz, 333 K, DMSO-d6): GC 
170.5, 168.7, 155.4, 137.3, 128.4, 128.1, 127.3, 127.0, 126.7, 126.4, 
78.0, 77.1, 51.2, 50.2, 41.6, 33.4, 27.9 (mixture of rotamers); HRMS 
(ESI) m/z: [M+H]+ calcd for C15H23N2O3 279.1703, found 279.1696.  
N-benzyl-N-methyl-2-(2-oxopyrrolidin-1-yl)acetamide (56). Purified 
by silica gel chromatography (1% MeOH/CH2Cl2), affording the title 
compound as a yellow solid (216 mg, 62%): ʆmax (neat) 2954, 2917, 
2876, 1684, 1645, 754, 705 cm-1; 1H NMR (400 MHz, 333 K, DMSO-
d6): GH 7.36  ? 7.22 (m, 5H), 4.57  ? 4.51 (m, 2H), 4.12 (s, 2H), 3.42 - 
3.39 (m, 2H), 2.92 -2.82 (m, 3H), 2.27  ? 2.19 (m, 2H), 1.99  ? 1.95 (m, 
2H) (mixture of rotamers); 13C NMR (101 MHz, 333 K, DMSO-d6): GC 
174.0, 167.1, 128.4, 128.1, 127.3, 126.8, 126.4, 54.5, 51.5, 50.1, 
47.0, 43.5, 33.6, 29.7, 17.3 (mixture of rotamers); HRMS (ESI) m/z: 
[M+H]+ calcd for C14H19N2O2 247.1441, found 247.1445.                   
N-methyl-N-(pyridin-3-ylmethyl)benzamide (57). Purified by silica 
gel chromatography (1% MeOH/CH2Cl2), affording the title 
compound as a yellow oil (225 mg, 70%): ʆmax (neat) 3057, 3030, 
2924, 1627, 1400, 1070, 1027, 787, 715, 702 cm-1; 1H NMR (400 
MHz, 333 K, DMSO-d6): GH 8.51 (dd, J = 4.7, 1.5 Hz, 2H), 7.70 (s, 1H), 
7.44 (s, 5H), 7.39 (dd, J = 7.8, 4.8 Hz, 1H), 4.64 (s, 2H), 2.89 (s, 3H); 
13C NMR (101 MHz, CDCl3): GC 171.9, 149.6, 149.2, 148.8, 136.2, 
135.9, 134.6, 132.8, 130.0, 128.6, 127.1, 123.9, 52.9, 48.6, 37.2, 
33.2 (mixture of rotamers); HRMS (ESI) m/z: [M+H]+ calcd for 
C14H15N2O 227.1179, found 227.1176. 
N-butyl-N-methylbenzamide (58).44 Purified by silica gel 
chromatography (1% MeOH/CH2Cl2), affording the title compound 
as a yellow oil (176 mg, 65%): ʆmax (neat) 2958, 2932, 2872, 1629, 
1402, 1072, 702 cm-1; 1H NMR (400 MHz, 333 K, DMSO-d6): GH 7.44 
 ? 7.41 (m, 3H), 7.36  ? 7.33 (m, 2H), 3.32 (s, 2H), 2.91 (s, 3H), 1.53 
(m, 2H), 1.23 (s, 2H), 0.85 (s, 3H); 13C NMR (101 MHz, CDCl3): GC  
172.1, 171.4, 137.0, 129.4, 128.5, 127.0, 126.8, 51.2, 47.3, 37.6, 
32.8, 30.5, 29.2, 20.2, 19.7, 14.0, 13.7 (mixture of rotamers); HRMS 
(ESI) m/z: [M+H]+ calcd for C12H18NO 192.1383, found 192.1379. 
 
General Method for for Chiral Secondary Amide Substrate Scope 
To an oven-dried, purged and sealed Schlenk tube containing 4-
(trifluoromethyl)phenol (46 mg, 0.28 mmol, 0.2 equiv.), KOAc (139 
mg, 1.42 mmol, 1 equiv.), ester (1.42 mmol, 1 equiv.) and THF (700 
ʅ> ? ǁĂƐ added benzylamine (155 µL, 1.42 mmol, 1 equiv.). The 
reaction mixture was heated at 90 °C for 22 h then diluted with 
EtOAc (10 mL), washed with brine (3 x 10 mL), dried over Na2SO4, 
and concentrated to a residue in vacuo which was purified by silica 
gel chromatography (MeOH/CH2Cl2 or Acetone/Pet. Ether 40  ? 60 
qC). 
 
benzyl (R)-(1-(benzylamino)-1-oxopropan-2-yl)carbamate (59).45 
Purified by silica gel chromatography (0.5% MeOH/CH2Cl2), 
affording the title compound as a white solid (235 mg, 53%): ʆmax 
(neat) 3284, 3060, 3034, 2978, 2932, 1684, 1644, 1526, 1258, 1228, 
1048, 698 cm-1; 1H NMR (400 MHz, CDCl3): GH  7.37  ? 7.22 (m, 10H), 
6.55 (s, 1H), 5.43 (s, 1H), 5.08  ? 5.01 (m, 2H), 4.46  ? 4.36 (m, 2H), 
4.29  ? 4.26 (m, 1H), 1.42  ? 1.37 (m, 3H); 13C NMR (101 MHz, CDCl3): 
GC 172.3, 156.2, 138.0, 136.2, 128.9, 128.7, 128.4, 128.2, 127.8, 
127.7, 67.2, 50.8, 43.7, 18.8; HRMS (ESI) m/z: [M+H]+ calcd for 
C18H21N2O3 313.1547, found 313.1545; ee = 100%; [D]D20 -10.2 (c = 
1.0, EtOH). 
benzyl (S)-(1-(benzylamino)-4-methyl-1-oxopentan-2-yl)carbamate 
(60).46  Purified by silica gel chromatography (1% MeOH/CH2Cl2), 
affording the title compound as a white solid (262 mg, 52%): ʆmax 
(neat) 3315, 3271, 3066, 2958, 2932, 1684, 1645, 1530, 1236, 1055, 
696 cm-1; 1H NMR (400 MHz, CDCl3): GH 7.38  ? 7.25 (m, 10H), 6.52 (s, 
1H), 5.30 (d, J = 7.7 Hz, 1H), 5.13  ? 5.05 (m, 2H), 4.49  ? 4.38 (m, 2H), 
4.25  ? 4.24 (m ,1H), 1.75  ? 1.65 (m, 2H), 1.58  ? 1.54 (m, 1H), 0.99  ? 
0.94 (m, 6H) ; 13C NMR (101 MHz, CDCl3): GC 172.2, 156.4, 138.0, 
136.2, 128.9, 128.7, 128.4, 128.2, 127.8, 127.7, 67.2, 53.8, 43.7, 
41.9, 41.6, 24.8, 23.1, 22.1; HRMS (ESI) m/z: [M+H]+ calcd for 
C21H27N2O3 355.2016, found 355.2016; ee = 96%; [D]D20 -16.0 (c = 
1.2, EtOH), lit [D]D22 -14.1 (c = 1.2, EtOH). 
benzyl(S)-(1-(benzylamino)-4-(methylthio)-1-oxobutan-2-
yl)carbamate (61).47 Purified by silica gel chromatography (0.5% 
MeOH/CH2Cl2), affording the title compound as a white solid (174 
mg, 33%): ʆmax (neat) 3280, 2915, 1690, 1642, 1534, 1256, 1238, 
1050, 1029, 698 cm-1; 1H NMR (400 MHz, CDCl3): GH 7.37  ? 7.23 (m, 
10H), 6.52 (s, 1H), 5.54 (d, J = 7.2 Hz, 1H), 5.10 (d, J = 11.6 Hz, 2H), 
4.49  ? 4.35 (m, 3H), 2.61 - 2.45 (m, 2H), 2.15  ? 1.95 (m, 6 H); 13C 
NMR (101 MHz, CDCl3): GC 171.0, 137.9, 128.9, 128.7, 128.4, 128.3, 
127.9, 127.8, 67.3, 54.1, 43.8, 31.7, 30.3, 15.3; HRMS (ESI) m/z: 
[M+H]+ calcd for C20H25N2O3S 373.1580, found 373.1580; ee = 89%; 
[D]D20 12.4 (c =  1.0, EtOH).                                      
(R)-N-benzyl-2-hydroxy-2-phenylacetamide (62).48 Purified by silica 
gel chromatography (1% MeOH/CH2Cl2), affording the title 
compound as a white solid (273 mg, 80%): ʆmax (neat) 3406, 3285, 
3183, 1647, 1539, 1455, 1068, 758, 707 cm-1; 1H NMR (400 MHz, 
CDCl3): GH  7.39  ? 7.24 (m, 8H), 7.17 (d, J = 7.4 Hz, 2H), 6.67 (s, 1H), 
5.02 -5.01 (m, 1H), 4.44  ? 4.34 (m, 2H), 3.89 - 3.86 (m, 1H); 13C NMR 
(101 MHz, CDCl3): GC 172.2, 139.6, 137.8, 128.9, 128.8, 128.8, 127.7, 
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126.9, 74.3, 43.5; HRMS (ESI) m/z: [M+H]+ calcd for C15H16NO2 
242.1176, found 242.1174; ee = 83%; [D]D20 -26.6 (c = 0.23, MeOH), 
lit [D]D20 -5.6 (c = 0.23, MeOH). 
(S)-N-benzyl-2-hydroxy-3-phenylpropanamide (63).49 Purified by 
silica gel chromatography (1% MeOH/CH2Cl2), affording the title 
compound as a white solid (241 mg, 67%): ʆmax (neat) 3366, 2919, 
1629, 1534, 1091, 1074, 702 cm-1; 1H NMR (400 MHz, CDCl3): GH  
7.34  ? 7.23 (m, 8H), 7.19 (d, J = 6.8 Hz, 2H), 6.82 ( br. s, 1H),  4.49  ? 
4.33 (m, 3H), 3.25 (dd, J = 13.9, 4.1 Hz, 1H), 2.94 (dd, J = 13.9, 8.2 
Hz, 1H), 2.70 (s, 1H); 13C NMR (101 MHz, CDCl3): GC 172.6, 138.0, 
136.9, 129.7, 128.9, 128.8, 127.9, 127.7, 127.2, 73.0, 43.2, 41.0; 
HRMS (ESI) m/z: [M+H]+ calcd for C16H18NO2 256.1332, found 
256.1333; ee = 98%; [D]D20 -55.7 (c = 3.4, EtOAc), lit [D]D20 -44.4 (c = 
3.4, EtOAc) 
(S)-N-benzyl-2-hydroxypropanamide (64).50 Purified by silica gel 
chromatography (1% MeOH/CH2Cl2), affording the title compound 
as a yellow oil (129 mg, 51%); %): ʆmax (neat) 3310, 1644, 1532, 
1273, 1122, 698 cm-1; 1H NMR (400 MHz, CDCl3): GH  7.34  ? 7.24 (m, 
5H), 7.04 (s, 1H), 4.42 (d, J = 5.9 Hz, 2H), 4.24 (qd, J = 6.8, 4.8 Hz, 
1H), 3.53 (d, J = 4.7 Hz, 1H), 1.42 (d, J = 6.8 Hz, 3H); 13C NMR (101 
MHz, CDCl3): GC 174.9, 138.0, 128.8, 127.8, 127.7, 115.7, 68.5, 43.2, 
21.4; HRMS (ESI) m/z: [M+H]+ calcd for C10H14NO2 180.1019, found 
180.1015; ee = 97%; [D]D20 -4.2 (c = 0.25, CHCl3), lit [D]D26 -21.5 (c = 
0.25, CHCl3) 
(R)-N-benzyl-2,2-dimethyl-1,3-dioxolane-4-carboxamide (65). 
Purified by silica gel chromatography (15% acetone/Pet. ether 40  ? 
60 qC), affording the title compound as an off-white solid (329 mg, 
98%): ʆmax (neat) 3332, 2988, 2932, 1649, 1537, 1221, 1029, 
839,735, 702 cm-1; 1H NMR (400 MHz, CDCl3): GH 7.36  ? 7.32 (m, 2H), 
7.30  ? 7.26 (m, 3H), 6.89 (br. s, 1H), 4.54 (dd, J = 7.6, 5.3 Hz, 1H), 
4.48 (d, J = 6.0 Hz, 2H), 4.31 (dd, J = 8.7, 7.6 Hz, 1H), 4.15 (dd, J = 
8.8, 5.3 Hz, 1H), 1.44 (s, 3H), 1.38 (s, 3H); ); 13C NMR (101 MHz, 
CDCl3): GC 171.2, 137.9, 128.9, 127.7, 127.7, 111.1, 75.21, 67.9, 43.1, 
26.3, 25.1; HRMS (ESI) m/z: [M+H]+ calcd for C13H18NO3 236.1281, 
found 236.1280; ee = 94%; [D]D20 +16.0 (c = 1.0, EtOH). 
(S)-N-benzyl-2-(4-isobutylphenyl)propanamide (66).51 Purified by 
silica gel chromatography (1% MeOH/CH2Cl2), affording the title 
compound as a yellow solid (61 mg, 15%): ʆmax (neat) 3299, 3030, 
2950, 2921, 2867, 1640, 1537, 1454, 1230, 737, 696 cm-1; 1H NMR 
(400 MHz, CDCl3): GH 7.27  ? 7.19 (m, 5H), 7.14 -7.10 (m, 4H), 6.61 (s, 
1H), 4.39 (d, J = 5.8 Hz, 2H), 3.58 (q, J = 7.2 Hz, 1H), 2.45 (d, J = 7.2 
Hz, 2H), 1.91  ? 1.78 (m, 1H), 1.55 (d, J = 7.2 Hz, 3H), 0.89 (d, J = 6.6 
Hz, 6H); 13C NMR (101 MHz, CDCl3): GC 174.5, 141.0, 138.6, 138.5, 
129.8, 128.7, 127.5, 127.5, 47.0, 45.1, 43.7, 30.3, 22.5, 18.6; HRMS 
(ESI) m/z: [M+H]+ calcd for C20H26NO 296.2009, found 296.2005; ee 
= 83%; [D]D20 +3.0 (c = 0.88, DCM), lit [D]D25 +7.2 (c = 0.88, DCM). 
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1. General
All reagents and solvents were obtained from commercial suppliers and were used without further 
purification unless otherwise stated. Purification was carried out according to standard laboratory 
methods.1 
1.1 Purification of Solvents
i) Anhydrous THF and toluene were obtained from a PureSolv SPS-400-5 solvent 
purification system.
ii) Acetonitrile, 1,2-Dichloroethane, isopropanol and 2-MeTHF were purified by fractional 
distillation under vacuum from CaH2; n-butanol was purified by stirring over 4 Å 
molecular sieves; CPME was purified by vacuum distillation from sodium metal; 1,4-
Dioxane was purified by vacuum distillation from LiAlH4; Dimethyl carbonate was 
purified by fractional distillation under vacuum from 4 Å molecular sieves; DMF was 
purified by fractional distillation under vacuum from MgSO4.
iii) Purified solvents were transferred to and stored in septum-sealed oven-dried flasks over 
previously activated 4 Å molecular sieves and purged with and stored under nitrogen.
1.2 Purification of Starting Materials
i) Methyl benzoate, benzylamine and N-methylbenzylamine used for optimisation 
reactions, were purified by vacuum distillation from KOH; trifluoroethanol, used as an 
additive, was purified by fractional distillation from Na2SO4.
ii) BEMP was purified by vacuum distillation from CaH2; Ca3(PO4)2, Cs2CO3, Cs3PO4, K2CO3, 
KH2PO4, K2HPO4, K3PO4, Li3PO4, Mg3(PO4)2 and Na3PO4 were stored in a vacuum oven at 
60 C; DABCO was recrystallised from MeOH/diethyl ether (1:1); DBU was purified by 
fractional distillation under vacuum; Et3N was purified by fractional distillation under 
vacuum over CaH2,  Potassium acetate was stored in a desiccator over P2O5; KOAc, KOH 
and KTFA were stored in a desiccator over P2O5; KOtBu was purified by sublimation.
iii) Dichloromethane, ethyl acetate, methanol, and petroleum ether 4060 °C for 
purification purposes were used as obtained from suppliers without further purification.
1.3 Experimental Details
i) All reactions were carried out using oven-dried glassware, which was evacuated and 
purged with N2 before use.
ii) Amidation reactions were performed using 25 mL Schlenk reaction vessels.
iii) Purging refers to a vacuum/nitrogen-refilling procedure.
iv) Room temperature was generally ca. 20 C.
v) Reactions were carried out at elevated temperatures using a temperature-regulated 
hotplate/stirrer.
vi) Amidation reactions at elevated temperatures were carried out using a STEM heating 
block.
vii) Reactions requiring the use of Radleys tubes with elevated temperatures were 
performed in a carousel resting on a temperature-regulated hotplate/stirrer.
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1.4 Purification of Products
i) Thin layer chromatography was carried out using Merck silica plates coated with 
fluorescent indicator UV254. These were analysed under 254 nm UV light or developed 
using potassium permanganate solution.
ii) Flash chromatography was carried out using ZEOprep 60 HYD 40-63 µm silica gel.
1.5 Analysis of Products
i) Fourier Transformed Infra-Red (FTIR) spectra were obtained using an A2 Technologies 
ATR 32 machine.
ii) 1H and 13C NMR spectra were obtained on a Bruker DRX 500 spectrometer at 500 and 
126MHz, respectively or on a Bruker AV3 400 at 400 and 101 MHz, respectively, or on a 
Bruker AVANCE 400 spectrometer at 400 and 101 MHz respectively. Chemical shifts are 
reported in ppm and coupling constants are reported in Hz with CDCl3 referenced at 
7.26 (1H) and 77.16 ppm (13C), and DMSO referenced at 2.50 (1H) and 39.52 ppm (13C).
iii) Variable temperature NMR experiments were obtained using a Bruker AVANCE 400 
spectrometer at 400 and 100 MHz respectively, or a Bruker DRX 500 spectrometer at 
500 and 126MHz, respectively  at 333 K.
iv) High-resolution mass spectra were obtained on a Thermofisher LTQ Orbitrap XL 
instrument at the EPSRC National Mass Spectrometry Service Centre (NMSSC), Swansea.
v) Reverse phase HPLC data was obtained on an Agilent 1200 series HPLC using a Machery-
Nagel Nucleodur C18 column.
vi) Chiral HPLC data was obtained on an Agilent 1260 Infinity HPLC using a Chiralpak IA 
column.
vii) Optical rotations were measured at 589 nm using a Perkin Elmer 341 Polarimeter
1.6 HPLC Methods
i) For N-Benzylbenzylamide 2: Reversed phase HPLC analysis was performed using a 
gradient method, eluting with 5  80% MeCN/H2O over 5 minutes at a flow rate of 2 
mL/min, with methyl benzoate, 2,2,2-trifluoroethyl benzoate intermediate, N-
benzylbenzamide product 2, and iodobenzene internal standard eluting at 2.0, 2.5, 1.9 
and 2.9 minutes, respectively
Time (min) Concentration of MeCN (%)
0 5
1 55
3.9 60
4.1 80
4.3 5
5 5
For N-benzyl-N-methylbenzamide 23: Reversed phase HPLC analysis was performed 
using a gradient method, eluting with 5  60% MeCN/H2O over 8 minutes at a flow rate 
of 2 mL/min, with methyl benzoate, N-methylbenzylamine, N-benzyl-N-
methylbenzamide product 23, and caffeine  internal standard eluting at 4.7, 1.0, 5.1 and 
2.0, respectively.
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Time (min) Concentration of MeCN (%)
0 5
5.5 60
5.8 5
8 5
ii) For N-Benzylbenzylamide 2: For reactions using an internal standard, prior HPLC 
calibration was carried out using samples containing varying molarities of product and 
iodobenzene, allowing calculation of the response factor by substituting values into the 
following equation:
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Screening reactions were carried out using a known molarity of iodobenzene internal 
standard as indicated in the relevant general experimental procedures.
Unknown molarities of product were calculated by rearranging the above equation, 
using the average value for the response factor as determined during calibration.
Conversion to product was calculated as a percentage of the theoretical molarity for the 
reaction.
For N-benzyl-N-methylbenzamide 23: Conversion factor established by running 3 
samples with a ratio of 0.25:1 caffeine:analyte, with the average conversion factor 
calculated by substituting values for each sample into the following equation:
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
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For standard sampling of reaction mixtures, the ratio of Caffeine:Analyte is 0.25:1.  
Therefore, when calculating the % conversion:
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iii) For N-Benzylbenzylamide 2: Samples for HPLC analysis were prepared by diluting a 10 M, 
aliquot from the reaction mixture to 1 mL with MeCN.
For N-benzyl-N-methylbenzamide 23: Samples for HPLC analysis were prepared through 
the addition of 7 mL of a 0.05 M caffeine standard to the completed reaction mixture. 
The resulting solution was then stirred before the removal of a 200 µL aliquot. The 
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aliquot was diluted to 1 mL with MeOH, a 200 µL aliquot of the diluted solution was then 
further diluted with 800 µL MeOH and then filtered for HPLC analysis against established 
conversion factors.
iv) For compounds 11, 63, 64, 65, 66 and 72: Chiral HPLC was performed using an isocratic 
method, using a Chiralpak IA column, eluting with 10% IPA/hexanes over 20 minutes 
with a flow rate of 1 mL/min.
For compound 59: Chiral HPLC was performed using an isocratic method, using a 
Chiralpak IA column, eluting with 5% IPA/hexanes over 1 hour with a flow rate of 1 
mL/min.
For compounds 60 and 61: Chiral HPLC was performed using an isocratic method, using a 
Chiralpak IA column, eluting with 10% IPA/hexanes over 1 hour with a flow rate of 1 
mL/min.
For compound 62: Chiral HPLC was performed using an isocratic method, using a 
Chiralpak IA column, eluting with 10% IPA/hexanes over 40 min with a flow rate of 1 
mL/min.
For compounds 69, 70 and 71: Chiral HPLC was performed using an isocratic method, 
using a ChiralpakIA column, eluting with 5% IPA/hexanes over 40 min with a flow rate of 
1 mL/min.
The major and minor enantiomers were found to elute as follows:
Product Major enantiomer retention 
time (min)
Minor enantiomer retention 
time (min)
11 8.44 11.78
59 38.34 N/A
60 11.16 17.24
61 24.78 51.32
62 15.34 24.06
63 11.91 10.12
64 9.38 8.87
65 8.79 10.31
66 9.13 16.91
69 34.01 N/A
70 18.17 N/A
71 50.66 N/A
72 9.37 N/A
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2. General Experimental Procedures
2.1 General Procedure A for Investigating the Nature of the Base Species
To an oven-dried, purged and sealed Schlenk tube containing trifluoroethanol (20 M, 0.28 mmol, 0.2 
equiv.), base (1.42 mmol, 1 equiv.) and THF (700 M,? was added methyl benzoate (178 µL, 1.42 
mmol, 1 equiv.) and benzylamine (155 µL, 1.42 mmol, 1 equiv.). The reaction mixture was heated at 
90 °C for 22 h. The reaction mixture was sampled at the end of the required reaction time and the 
conversion was determined by HPLC with reference to iodobenzene (1.4 M), which was used as an 
internal standard.
Entry Base pKa Conversion (%)
1 KTFA 0 1
2 KH2PO4 2 1
3 KOAc 6 1
4 K2HPO4 7 1
5 K2CO3 10 2
6 K3PO4 12 78
7 KOH 16 5
8 KOtBu 18 47
9 Ca3PO4 13 1
10 Cs3PO4 13 1
11 Li3PO4 13 0
12 Mg3PO4 13 16
13 Na3PO4 13 1
14 Cs2CO3 10 11
15 NMO 7 13
16 DABCO 9 4
17 Et3N 11 1
18 DBU 12 61
19 BEMP 19 8
2.2 General Procedure B for Optimisation of the TFE Mediated Tertiary Amide Formation: 
Additive Screen
To an oven-dried, purged and sealed Schlenk tube containing additive (0.28 mmol, 0.2 equiv.), K3PO4 
(301 mg, 1.42 mmol, 1 equiv.) and THF (700 M,? was added methyl benzoate (178 µL, 1.42 mmol, 1 
equiv.) and N-methylbenzylamine (183 µL, 1.42 mmol, 1 equiv.) was added and the reaction mixture 
was heated at 90 °C for 22 h. The reaction mixture was sampled at the end of the required reaction 
time and the conversion was determined by HPLC with reference to a 0.05M caffeine solution.
Entry Additive Conversion (%)
1 4-CF3C6H4OH 1
2 HFIP 0
S8
3 HOAt 0
4 HOBt 0
5 HOCt 0
6 N-hydroxysuccinimide 0
7 Oxyma 0
8 2-Picoline N-oxide 0
9 TFE 1
2.3 General Procedure C for Optimisation of the TFE Mediated Tertiary Amide Formation: 
Base and Solvent Screen
To an oven-dried, purged and sealed Schlenk tube containing trifluoroethanol (20 µL, 0.28 mmol, 0.2 
equiv.), base (1.42 mmol, 1 equiv.) and solvent (700 M,? was added methyl benzoate (178 µL, 1.42 
mmol, 1 equiv.) and N-methylbenzylamine (183 µL, 1.42 mmol, 1 equiv.) was added and the reaction 
mixture was heated at 90 °C for 22 h. The reaction mixture was sampled at the end of the required 
reaction time and the conversion was determined by HPLC with reference to a 0.05M caffeine 
solution.
Entry Base Solvent Conversion (%)
1 DABCO n-butanol 0
2 K3PO4 n-butanol 3
3 DBU n-butanol 2
4 KOtBu n-butanol 22
5 DABCO CPME 0
6 K3PO4 CPME 37
7 DBU CPME 4
8 KOtBu CPME 96
9 DABCO DCE 0
10 K3PO4 DCE 0
11 DBU DCE 0
12 KOtBu DCE 0
13 DABCO 1,4-Dioxane 0
14 K3PO4 1,4-Dioxane 12
15 DBU 1,4-Dioxane 3
16 KOtBu 1,4-Dioxane 37
17 DABCO DMC 0
18 K3PO4 DMC 0
19 DBU DMC 0
20 KOtBu DMC 0
21 DABCO DMF 0
22 K3PO4 DMF 8
23 DBU DMF 3
24 KOtBu DMF 21
25 DABCO IPA 0
26 K3PO4 IPA 9
27 DBU IPA 2
28 KOtBu IPA 0
29 DABCO 2-MeTHF 1
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30 K3PO4 2-MeTHF 43
31 DBU 2-MeTHF 5
32 KOtBu 2-MeTHF 2
33 DABCO MeCN 0
34 K3PO4 MeCN 0
35 DBU MeCN 4
36 KOtBu MeCN 32
37 DABCO THF 2
38 K3PO4 THF 1
39 DBU THF 8
40 KOtBu THF 56
2.4 General Procedure D for Optimisation of the TFE Mediated Tertiary Amide Formation: 
Elevated Temperature Screen
To an oven-dried, purged and sealed Schlenk tube containing trifluoroethanol (20 µL, 0.28 mmol, 0.2 
equiv.), K3PO4 (301 mg, 1.42 mmol, 1 equiv.) and solvent (700 M,? was added methyl 4-
(trifluoromethyl)benzoate (229 µL, 1.42 mmol, 1 equiv.) and the reaction heated at the desired 
temperature for 30 min. N-methylbenzylamine (183 µL, 1.42 mmol, 1 equiv.) was then added and 
the reaction mixture was heated at the desired temperature for a further 22 h. The reaction mixture 
was sampled at the end of the required reaction time and the conversion was determined by HPLC 
with reference to a 0.05M caffeine solution.
Entry Solvent Temperature (C) Conversion (%)
1 THF 90 0
2a THF 90 70
3a,b THF 90 62
4a CPME 125 77c
5a 1,4-dioxane 125 93c
6a 2-MeTHF 100 72c
7a,d 1,4-dioxane 125 0c
8a,e 1,4-dioxane 125 0c
9a,f 1,4-dioxane 125 0c
aPreformation of the active ester intermediate for 30 min at reaction temperature. bMethyl benzoate used as 
ester substrate. cIsolated Yield. dPerformed in the absence of K3PO4. ePerformed in the absence of TFE. 
fPerformed in the absence of both K3PO4 and TFE.
2.5 General Procedure E for Chiral Secondary Amide Base Screen
To an oven-dried, purged and sealed Schlenk tube containing 4-(trifluoromethyl)phenol (46 mg, 0.28 
mmol, 0.2 equiv.), base (1.42 mmol, 1 equiv.), Boc-L-phenylalanine methyl ester (397 mg, 1.42 
mmol, 1 equiv.)  and THF (700 M,? was added benzylamine (155 µL, 1.42 mmol, 1 equiv.). The 
reaction mixture was heated at 90 °C for 22 h then diluted with EtOAc (10 mL), washed with brine (3 
x 10 mL), dried over Na2SO4, and concentrated to a residue in vacuo which was purified by silica gel 
chromatography (1% MeOH/CH2Cl2).
Entry Base Base pKa Yield (%) ee (%)
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1 KTFA 0 46 93
2 KH2PO4 2 62 87
3 KOAc 6 55 92
4 NMO 7 36 92
5 K2HPO4 7 48 92
6 DABCO 9 40 85
7 K2CO3 10 46 75
8 Cs2CO3 10 34 40
9 DBU 12 69 16
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2.6 General Procedure F for Chiral Secondary Amide Additive Screen
To an oven-dried, purged and sealed Schlenk tube containing additive (0.28 mmol, 0.2 equiv.), KOAc 
(139 mg, 1.42 mmol, 1 equiv.), Boc-L-phenylalanine methyl ester (397 mg, 1.42 mmol, 1 equiv.) and 
THF (700 M,? was added benzylamine (155 µL, 1.42 mmol, 1 equiv.). The reaction mixture was 
heated at 90 °C for 22 h then diluted with EtOAc (10 mL), washed with brine (3 x 10 mL), dried over 
Na2SO4, and concentrated to a residue in vacuo which was purified by silica gel chromatography (1% 
MeOH/CH2Cl2).
Entry Additive Additive pKa Yield (%) ee (%)
1 Picoline n-oxide - 28 87
2 HOCt 2.2 54 91
3 HOAt 3.3 32 89
4 HOBt 4.6 47 91
5 Oxyma 4.6 50 93
6 NHS 7.8 58 79
7 4-CF3C6H4OH 8.7 55 92
8 HFIP 9.3 35 89
9 TFE 12.5 31 89
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10a 4-CF3C6H4OH 8.7 44 92
11 No additive - 17 89
12a No additive - 28 88
aPerformed in the absence of KOAc
2.8 General Procedure G for Investigating the Point of Racemisation in the Chiral 
Secondary Amide Methodology.
To an oven-dried, purged and sealed Schlenk tube containing  KOAc  (1 equiv.), Boc-L-phenylalanine 
methyl ester (397 mg, 1.42 mmol, 1 equiv.) or amide 11 (150 mg, 0.43 mmol, 1 equiv.) was added 
THF (700/210 M, respectively). The reaction mixture was heated at 90 °C for 22 h then diluted with 
EtOAc (10 mL), washed with brine (3 x 10 mL), dried over Na2SO4, and concentrated to a residue in 
vacuo. The ee of the resulting products was then determined by HPLC.
Entry Substrate Initial ee (%) ee upon reaction 
completion (%)
1 Boc-Phe-OMe 100 100
2 11 92 92
2.7 General Procedure H for Synthesis of Secondary Amine Starting Materials
To a round-bottomed flask containing a solution of amine (1 equiv.) in DCM (10 mL) at 0 C was 
added Et3N (2 equiv.) and a solution of di-tert-butyl dicarbonate (1.2 equiv.) in DCM (5 mL). Reaction 
warmed to room temperature and stirred for 16 h, at which point it was washed sequentially with 
2M HCl (10 mL), 5% NaHCO3 (aq) (10 mL) and water (10 mL). Organics dried over Na2SO4 and 
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concentrated to a residue in vacuo, to which was added THF (10 mL) and NaH (1.1 equiv.) reaction 
stirred until effervescence had ceased, at which point methyl iodide (1.2 equiv.) was added and the 
reaction heated at 45 C for 72 hours. THF removed in vacuo, the resulting crude product dissolved 
in EtOAc (10 mL), washed with water (3 x 10 mL), dried over Na2SO4 and concentrated to a residue in 
vacuo which was purified by silica gel chromatography (5% EtOAc/Pet. ether 4060 °C).
To a solution of the resulting N-methylated Boc-protected amine in DCM (10 mL) was added TFA (10 
mL). Reaction stirred at room temperature for 16 h, at which point the reaction mixture was 
concentrated to a residue in vacuo. Resulting crude product dissolved in EtOAc (10 mL) and washed 
with 2M NaOH (aq) until pH O 9. Organics extracted with EtOAc (3 x 20 mL), dried over Na2SO4 and 
concentrated in vacuo to afford the desired N-methyl amine.
2.8 General Procedure I for Synthesis of Chiral Ester Starting Materials v Esterification
To an oven-dried, purged Radleys tube containing carboxylic acid (1 equiv.) was added MeOH (20 
mL), and the solution cooled to 0 C. SOCl2 (1.2 equiv.) added dropwise and the reaction refluxed for 
16 h. Reaction mixture washed with saturated NaHCO3 (aq) until pH O 8, extracted with DCM (3 x 20 
mL), dried over Na2SO4 and concentrated to a residue in vacuo. Resulting crude product was purified 
by silica gel chromatography (EtOAc/Pet. ether 4060 °C).
2.9 General Procedure J for Synthesis of Chiral Ester Starting Materials 
v
 Cbz Protection
To a round-bottomed flask was added ester hydrochloride salt (1 equiv.), N-
(benzyloxycarbonyloxy)succinimide (1.1 equiv.), NaHCO3 (2.5 equiv.), THF (7 mL) and water (7 mL). 
Reaction stirred for 16 h at room temperature, at which point the reaction mixture was diluted with 
water (20 mL) and extracted with EtOAc (2 x 20 mL). Organics dried over Na2SO4 and concentrated to 
a residue in vacuo which was purified by silica gel chromatography (EtOAc/pet. ether 4060 °C).
3. Characterisation Data
3.1 Characterisation Data for Synthesised Starting Materials 
N-methyl-3-phenylpropan-1-amine (67).2
N
H
Synthesised according to General Experimental Procedure H using 3.7 mmol of 3-phenylpropan-1-
amine, affording the title compound as a pale yellow liquid (372 mg, 67%).
max (neat): 3027, 2932, 2857, 2794, 1673, 1455, 1033, 748, 700 cm-1
1H NMR (500 MHz, DMSO-d6):  7.27, (t, J = 7.5 Hz, 2H), 7.17 (dd, J  = 16.9, 7.5 Hz, 3H), 2.59 (t, J = 7.6 
Hz, 2H), 2.45 (t, J = 7.0 Hz), 1.68 (p, J = 7.8 Hz, 5H) 
13C NMR (126 MHz, DMSO-d6):  142.2, 128.2, 128.2, 125.6, 50.9, 36.1, 32.9, 31.0
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HRMS m/z: [M+H]+ Calcd for C10H16N 150.1277, Found 150.1275
1-cyclohexyl-N-methylmethanamine (68).3
N
H
Synthesised according to General Experimental Procedure H using 8.8 mmol of 
cyclohexylmethanamine, affording the title compound as a pale yellow liquid (404 mg, 36%).
max (neat): 2919, 2850, 2788, 1448, 1126, 1150, 742 cm-1
1H NMR (500 MHz, CDCl3):  2.41 (d, J = 9.2 Hz, 4H), 1.74  1.64 (m, 5H), 1.49  1.42 (m, 2H), 1.28 -
1.10 (m, 3H), 0.95  0.87 (m, 2H) 
13C NMR (126 MHz,CDCl3):  54.3, 44.4, 35.5, 34.4, 33.2, 29.7, 29.7, 25.6, 25.6, 25.0, 25.0
HRMS m/z: [M+H]+ Calcd for C8H18N 128.1434, Found 128.1429
Methyl ((benzyloxy)carbonyl)-D-alaninate (69).4
O
O
CbzHN
Synthesised according to General Experimental Procedure J, using 3.58 mmol of methyl D-alaninate 
hydrochloride, and purified by flash column chromatography (20% EtOAc/Pet. ether 40  60 C) to 
afford the title compound as a pale yellow oil (581 mg, 68%).
max (neat): 3336, 3036, 2993, 2958, 1753, 1684, 1526, 1215, 1174, 1076, 754, 702 cm-1
1H NMR (400 MHz, CDCl3):  7.39  7.29 (m, 5H), 5.31 (s, 1H), 5.11 (m, 2H), 4.40 (p, J = 7.2 Hz, 1H), 
3.75 (s, 3H), 1.42 (d, J = 7.2 Hz, 3H)
13C NMR (101 MHz,CDCl3):  173.6, 155.7, 136.4, 128.6, 128.3, 128.2, 67.0, 52.5, 49.7, 18.8 
HRMS m/z: [M+H]+ Calcd for C12H16NO4 238.1074, Found 238.1076
ee = 100% 
Methyl ((benzyloxy)carbonyl)-L-leucinate (70).5
O
O
NHCbz
Synthesised according to General Experimental Procedure J, using 2.75 mmol of methyl L-leucinate 
hydrochloride, and purified by flash column chromatography (20% EtOAc/Pet. ether 40  60 C) to 
afford the title compound as a  colourless oil (683 mg, 89%). 
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max (neat): 3339, 2956, 1699, 1526, 1262, 1208, 1171, 1046, 739, 700 cm-1
1H NMR (500 MHz, CDCl3):  7.36  7.30 (m, 5H), 5.12 (m, 3H), 4.4 (dd, J = 13.8, 8.8 Hz, 1H), 3.74 (s, 
3H), 1.74  1.61 (m, 2H), 1.55  1.49 (m, 1H), 0.94 (m, 6H)
13C NMR (126 MHz,CDCl3):  173.8, 156.1, 136.4, 128.7, 128.3, 128.3, 67.1, 52.6, 52.4, 24.9, 23.0, 
22.0
HRMS m/z: [M+H]+ Calcd for C15H22NO4 280.1543, Found 280.1541
ee = 100%
ethyl ((	
	L-methioninate (71).6
O
O
S
NHCbz
Synthesised according to General Experimental Procedure J, using 2.81 mmol of methyl L-
methioninate hydrochloride, and purified by flash column chromatography (20% EtOAc/Pet. ether 
40  60 C) to afford the title compound as a pale yellow oil (629 mg, 72%).
max (neat): 3326, 2980, 2917, 1705, 1521, 1210, 1046, 1029, 700 cm-1
1H NMR (500 MHz, CDCl3):  7.36  7.29 (m, 5H), 5.42 (s, 1H), 5.11 (s, 2H), 4.48 (dd, J = 12.7, 7.6 Hz, 
1H), 4.21 (q, J = 7.1 Hz, 2H), 2.58 - 2.47 (m, 2H), 2.20  2.09 (m, 4H), 1.96 (td,  J = 14.4, 7.5 Hz, 1H), 
1.28 (t, J = 7.1Hz, 3H)    
13C NMR (126 MHz,CDCl3):  172.1, 156.0, 136.3, 128.7, 128.3, 128.3, 67.2, 61.8, 53.4, 32.2, 30.0, 
15.6, 14.3
HRMS m/z: [M+H]+ Calcd for C15H22NO4S 312.1264, Found 312.1261
ee = 100% 
Methyl (R)-2-hydroxy-2-phenylacetate (72).7
O
O
OH
Synthesised according to General Experimental Procedure I, using 4.93 (mmol) of (R)-2-hydroxy-2-
phenylacetic acid, and purified by flash column chromatography (20% EtOAc/Pet. ether 40  60 C) 
to afford the title compound as a colourless oil (643 mg, 80%).
max (neat): 3434, 1738, 1206, 1191, 1068, 977, 739, 696 cm-1 
1H NMR (400 MHz, CDCl3):  7.43 -7.31 (m, 5H), 5.18 (d, J = 5.3 Hz, 1H), 3.76 (d, J = 1.7 Hz, 3H), 3.49  
3.43 (m, 1H)
13C NMR (101 MHz,CDCl3):  174.3, 138.4, 128.8, 128.7, 126.7, 73.0, 53.2
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HRMS m/z: [M+H]+ Calcd for C9H11O3 167.0703, Found 167.0701
ee = 100% 
Methyl (S)-2-(4-isobutylphenyl)propanoate (73).8
O
O
Synthesised according to General Experimental Procedure I, using 3.64 mmol of (S)-2-(4-
isobutylphenyl)propanoic acid, and purified by flash column chromatography (10% EtOAc/Pet. ether 
40  60 C) to afford the title compound as a pale yellow oil (583 mg, 73%).
max (neat): 2954, 2870, 1738, 1206, 1163, 1066 cm-1
1H NMR (400 MHz, CDCl3):  7.21  7.18 (m, 2H), 7.11  7.09 (m, 2H), 3.70 (q, J = 7.2 Hz, 1H), 3.66 (s, 
3H), 2.45 (d, J = 7.2 Hz, 2H), 1.92  1.76 (m, 1H), 1.49 (d, J = 7.2 Hz, 3H), 0.90 (d, J = 6.6 Hz, 6H)
13C NMR (101 MHz,CDCl3):  175.4, 140.7, 137.9, 129.5, 127.3, 52.1, 45.2, 30.3, 22.5, 18.8
HRMS m/z: [M+H]+ Calcd for C14H21O2 221.1536, Found 221.15
4. 1H and 13C Spectra for Exemplified Compounds
N--N-ﬀﬁﬂﬃ (23). 
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0102030405060708090100110120130140150160170180190200
f1 (ppm)
3
3
.2
6
3
7
.0
9
5
0
.8
9
5
5
.2
7
1
2
6
.9
2
1
2
7
.0
8
1
2
7
.6
6
1
2
8
.2
9
1
2
8
.5
4
1
2
8
.8
7
1
2
9
.7
1
1
3
6
.3
8
1
3
6
.7
3
1
3
7
.1
7
1
7
1
.7
0
1
7
2
.4
3
N !"#$%& N '")*%& + ,)./0&12.2'")*%&3!"#$4'/5" (24)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
f1 (ppm)
2
.9
9
2
.0
0
4
.7
8
1
.9
6
1
.9
3
2
.8
5
4
.4
4
4
.4
8
4
.6
9
7
.2
3
7
.2
8
7
.2
9
7
.3
1
7
.3
6
7
.3
7
7
.3
9
7
.6
6
7
.6
7
7
.7
8
7
.7
9
N
O
F3C
N
O
23
24
S17
0102030405060708090100110120130140150160170180190200
f1 (ppm)
3
2
.4
8
3
6
.3
6
4
9
.7
7
5
3
.7
9
1
2
0
.4
1
1
2
2
.5
7
1
2
4
.7
4
1
2
5
.0
7
1
2
5
.1
0
1
2
5
.1
3
1
2
5
.1
6
1
2
6
.9
0
1
2
7
.0
3
1
2
7
.2
6
1
2
8
.3
5
1
2
9
.1
0
1
2
9
.3
6
1
2
9
.6
1
1
2
9
.8
7
1
3
6
.7
6
1
4
0
.2
8
1
6
9
.0
1
N6789:;<6=6>;?9@6N6A8BC;<789:?ADE8 (25)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
f1 (ppm)
3
.1
4
2
.2
3
4
.8
6
2
.0
6
2
.0
0
2
.8
5
4
.6
6
7
.2
8
7
.3
0
7
.3
1
7
.3
4
7
.3
6
7
.3
8
7
.3
9
7
.6
1
7
.6
3
7
.8
8
7
.9
0
N
O
F3C
24
N
O
NC
25
S18
0102030405060708090100110120130140150160170180190200
f1 (ppm)
3
3
.5
4
3
6
.8
9
5
1
.0
1
5
5
.1
0
1
1
3
.6
1
1
1
8
.2
1
1
2
6
.6
3
1
2
7
.6
4
1
2
7
.8
3
1
2
7
.9
4
1
2
8
.0
8
1
2
8
.4
0
1
2
8
.9
8
1
2
9
.2
0
1
3
2
.5
3
1
3
5
.9
7
1
3
6
.5
5
1
4
0
.6
6
1
4
0
.7
7
1
6
9
.6
6
1
7
0
.3
5
NFGHIJKLFMFNOLPQPFNFRHSOKLGHIJTRUVH (26)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
f1 (ppm)
3
.0
6
2
.0
0
2
.7
1
2
.1
0
3
.9
9
2
.8
6
4
.5
9
7
.2
7
7
.2
8
7
.2
9
7
.3
1
7
.3
5
7
.3
7
7
.3
9
7
.3
9
7
.4
5
7
.4
6
7
.4
7
7
.4
8
7
.5
0
7
.5
0
N
O
NC
25
N
O
Cl
26
S19
0102030405060708090100110120130140150160170180190200
f1 (ppm)
3
3
.5
3
3
7
.1
1
5
1
.0
5
5
5
.2
9
1
2
6
.7
2
1
2
7
.8
0
1
2
8
.3
6
1
2
8
.5
1
1
2
8
.6
8
1
2
8
.8
5
1
3
4
.7
1
1
3
5
.8
5
1
3
6
.4
9
1
3
6
.9
4
1
7
0
.6
6
1
7
1
.3
3
NWXYZ[\]W^W_Y`bcd\WNW_Y`b\]XYZ[e_fgY (28)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
f1 (ppm)
2
.9
4
2
.8
6
2
.0
0
1
.9
4
2
.6
8
3
.7
9
2
.8
8
3
.8
0
4
.6
0
6
.9
6
6
.9
6
6
.9
7
6
.9
8
6
.9
8
6
.9
9
7
.2
6
7
.2
6
7
.2
7
7
.2
8
7
.2
8
7
.3
0
7
.3
0
7
.3
5
7
.3
6
7
.3
7
7
.3
8
7
.3
8
7
.3
9
7
.3
9
7
.4
0
7
.4
0
7
.4
2
7
.4
2
7
.4
3
N
O
Cl
26
N
O
MeO
28
S20
0102030405060708090100110120130140150160170180190200
f1 (ppm)
3
3
.6
1
3
7
.3
0
5
1
.1
6
5
5
.4
2
1
1
3
.7
7
1
2
6
.8
7
1
2
7
.5
9
1
2
8
.4
2
1
2
8
.8
7
1
2
9
.0
8
1
3
7
.1
6
1
6
0
.8
2
1
7
1
.8
0
NhijklmnhohpjqrstmhNhpjqrmnijklupwxj (29)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
f1 (ppm)
2
.9
4
2
.9
8
2
.0
0
2
.9
2
5
.7
6
2
.8
6
3
.7
6
4
.5
8
6
.9
5
6
.9
5
6
.9
6
6
.9
7
6
.9
7
6
.9
8
6
.9
9
6
.9
9
7
.0
0
7
.0
1
7
.0
1
7
.2
7
7
.2
9
7
.3
1
7
.3
3
7
.3
5
7
.3
6
7
.3
7
7
.3
8
7
.3
9
7
.3
9
N
O
MeO
28
N
O
OMe
29
S21
0102030405060708090100110120130140150160170180190200
f1 (ppm)
3
3
.3
5
3
7
.0
9
5
0
.8
9
5
5
.3
8
1
1
2
.1
4
1
1
2
.5
8
1
1
5
.5
3
1
1
5
.9
0
1
1
9
.0
3
1
1
9
.2
4
1
2
6
.8
4
1
2
7
.6
8
1
2
8
.3
2
1
2
8
.9
4
1
2
9
.7
2
1
5
9
.7
0
Nyz{|}~yy{~yNy{~z{|}{ (30)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
f1 (ppm)
1
.8
2
1
.1
8
3
.0
0
0
.7
9
1
.1
9
8
.8
9
2
.6
8
2
.8
8
3
.7
8
3
.8
3
4
.3
0
4
.6
9
5
.7
1
6
.9
5
6
.9
7
6
.9
9
7
.0
1
7
.0
2
7
.0
4
7
.0
6
7
.0
8
7
.0
9
7
.1
1
7
.1
4
7
.1
6
7
.2
1
7
.2
1
7
.2
2
7
.2
3
7
.2
5
7
.2
7
7
.2
9
7
.3
1
7
.3
3
7
.3
4
7
.3
6
7
.3
7
7
.3
8
7
.4
0
7
.4
2
7
.4
2
N
O
OMe
29
N
O
OMe
30
S22
0102030405060708090100110120130140150160170180190200
f1 (ppm)
3
1
.6
0
3
5
.0
5
4
9
.1
1
5
3
.2
7
5
5
.2
0
5
5
.3
9
1
1
1
.4
1
1
2
0
.2
8
1
2
0
.4
9
1
2
6
.6
8
1
2
7
.0
7
1
2
8
.1
5
1
2
9
.9
3
1
3
6
.6
5
1
3
7
.0
8
1
5
4
.7
0
1
6
8
.1
5
NŁN-methylnicotinamide (31)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
f1 (ppm)
3
.0
0
2
.0
9
5
.7
8
0
.9
5
1
.8
7
2
.9
0
4
.6
2
7
.2
8
7
.3
0
7
.3
1
7
.3
6
7
.3
8
7
.4
0
7
.4
4
7
.4
5
7
.4
6
7
.4
7
7
.8
5
7
.8
7
8
.6
3
8
.6
4
N
O
OMe
30
N
N
O
31
S23
0102030405060708090100110120130140150160170180190200
f1 (ppm)
3
3
.6
2
3
7
.0
8
5
1
.0
9
5
5
.2
8
1
2
3
.5
0
1
2
6
.6
7
1
2
7
.8
7
1
2
8
.3
7
1
2
8
.9
5
1
2
9
.1
4
1
3
2
.2
1
1
3
4
.7
7
1
3
5
.0
6
1
3
6
.1
4
1
3
6
.6
7
1
4
7
.8
7
1
4
8
.1
0
1
5
0
.8
6
1
6
9
.1
2
1
6
9
.8
1
NN-methylfuran-2-carboxamide (32)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
f1 (ppm)
2
.7
9
2
.0
0
0
.8
9
0
.8
8
2
.7
8
1
.8
9
0
.8
4
3
.0
6
4
.7
2
6
.6
0
6
.6
0
6
.6
0
6
.6
1
7
.0
0
7
.2
6
7
.2
8
7
.2
8
7
.3
5
7
.3
6
7
.8
0
N
N
O
31
N
O
O
32
S24
0102030405060708090100110120130140150160170180190200
f1 (ppm)
3
4
.3
6
3
5
.9
2
5
2
.0
0
5
4
.3
3
1
1
1
.3
8
1
1
6
.6
3
1
2
7
.0
6
1
2
7
.6
4
1
2
8
.2
6
1
2
8
.8
4
1
3
7
.0
3
1
4
4
.0
8
1
4
8
.1
0
1
6
0
.6
2
NN-methyl-2-phenylacetamide (33)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
f1 (ppm)
1
.1
0
2
.0
4
2
.1
7
1
.3
3
0
.8
1
1
0
.0
0
2
.8
2
2
.9
4
3
.7
7
4
.5
3
4
.6
2
7
.2
0
7
.2
1
7
.2
2
7
.2
4
7
.2
7
7
.2
9
7
.3
1
N
O
O
32
N
O
33
S25
-100102030405060708090100110120130140150160170180190200210
f1 (ppm)
3
4
.8
3
4
9
.8
9
5
2
.6
4
1
2
6
.0
0
1
2
6
.6
7
1
2
7
.2
2
1
2
7
.9
0
1
2
8
.0
8
1
2
8
.7
2
1
2
8
.7
3
1
2
8
.7
4
1
2
8
.7
7
1
2
8
.8
0
1
3
5
.5
4
1
3
7
.5
4
1
7
0
.1
9
N ¡¢£¤N-methyl-2-(pyridin-2-yl)acetamide (34)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
f1 (ppm)
1
.0
9
1
.8
2
0
.6
9
1
.2
1
1
.3
3
0
.8
0
3
.4
6
2
.9
9
0
.9
4
0
.8
6
2
.8
2
2
.9
9
3
.9
1
3
.9
4
4
.5
4
4
.6
9
7
.2
3
7
.2
5
7
.3
1
7
.3
3
7
.7
1
7
.7
3
7
.7
5
8
.4
9
N
O
33
N
O
N
34
S26
0102030405060708090100110120130140150160170180190200
f1 (ppm)
3
3
.0
6
3
4
.9
5
4
2
.5
7
4
9
.8
6
5
2
.6
5
1
2
1
.3
6
1
2
3
.5
3
1
2
6
.4
2
1
2
6
.6
3
1
2
7
.2
0
1
2
8
.0
6
1
3
6
.0
4
1
4
8
.5
9
1
5
5
.9
8
1
6
9
.4
6
N¥¦§¥¨©ª«¬­®¯©°±®²³¥N¥¨©ª«®²¯©°±´¨µ¶© (39)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
f1 (ppm)
3
.0
5
3
.0
7
2
.0
0
1
.9
6
0
.9
4
1
.1
3
4
.8
7
2
.8
6
3
.7
6
4
.5
4
6
.9
6
6
.9
7
6
.9
9
7
.0
1
7
.1
8
7
.2
6
7
.2
6
7
.2
8
7
.2
9
7
.3
0
7
.4
2
N
O
N
34
N
O
MeO
39
S27
0102030405060708090100110120130140150160170180190200
f1 (ppm)
3
3
.4
0
3
7
.4
5
4
5
.5
3
5
0
.7
3
5
5
.1
8
5
5
.4
5
1
1
0
.3
9
1
2
0
.6
8
1
2
0
.8
0
1
2
4
.8
1
1
2
7
.0
0
1
2
7
.8
0
1
2
8
.3
9
1
2
8
.7
5
1
2
9
.2
7
1
2
9
.5
9
1
3
6
.5
6
1
3
6
.7
6
1
5
7
.2
7
1
5
7
.8
4
1
7
1
.6
8
1
7
2
.6
8
N-methyl-N·¸¹º»º¼¹½¾¿º»ÀÁÂÃÄº (40)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
f1 (ppm)
5
.0
0
2
.1
8
6
.8
3
3
.3
1
2
.8
6
3
.5
4
7
.1
9
7
.2
1
7
.2
2
7
.2
6
7
.2
8
7
.3
8
7
.3
9
7
.4
0
7
.4
1
7
.4
2
7
.4
3
N
O
MeO
39
N
O
40
S28
0102030405060708090100110120130140150160170180190200
f1 (ppm)
3
3
.1
6
3
3
.5
7
3
4
.9
0
3
8
.3
7
4
9
.4
8
5
3
.0
7
1
2
6
.5
6
1
2
7
.0
1
1
2
8
.4
3
1
2
8
.7
4
1
2
8
.8
8
1
2
9
.0
3
1
2
9
.3
0
1
2
9
.5
1
1
3
6
.7
0
1
3
8
.0
3
1
3
9
.1
7
1
7
1
.4
2
1
7
2
.2
5
N-methyl-NÅÆÇÅÈÉÊËÌÍÈÎÏÈÌÍÐÑÊËÒÓÔÕÖÊ (41)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
f1 (ppm)
2
.1
8
3
.9
3
3
.1
6
2
.0
0
9
.9
5
1
.8
5
1
.8
7
1
.8
9
2
.5
0
2
.9
2
3
.3
2
3
.3
5
7
.1
4
7
.1
6
7
.1
8
7
.2
3
7
.2
5
7
.3
3
7
.3
4
7
.3
5
7
.3
7
7
.3
9
7
.4
0
7
.4
0
7
.4
1
7
.4
2
N
O
40
N
O
41
S29
0102030405060708090100110120130140150160170180190200
f1 (ppm)
2
8
.7
8
2
9
.9
3
3
2
.7
9
3
2
.9
3
3
3
.3
6
3
7
.6
2
4
7
.4
0
5
1
.0
2
1
2
6
.1
5
1
2
6
.7
0
1
2
7
.0
0
1
2
8
.2
4
1
2
8
.5
0
1
2
8
.5
8
1
2
9
.4
5
1
3
6
.8
3
1
4
0
.9
0
1
4
1
.7
6
1
7
1
.5
2
1
7
2
.1
0
N-methyl-N×ØÙÚÛÜÝÜÞ×ß×ÚàáâãäÚàåæâÞçèáÜÝâ (43)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
f1 (ppm)
3
.0
0
2
.1
6
1
.7
6
4
.7
6
0
.9
6
0
.8
7
2
.9
5
4
.6
6
7
.2
8
7
.2
8
7
.2
8
7
.2
9
7
.2
9
7
.2
9
7
.3
0
7
.3
0
7
.3
0
7
.3
1
7
.3
1
7
.3
1
7
.4
4
7
.7
7
7
.7
7
7
.7
9
7
.7
9
8
.5
5
8
.5
5
8
.5
5
8
.5
6
8
.5
6
8
.5
6
8
.5
7
N
O
41
N
O
N
43
S30
0102030405060708090100110120130140150160170180190200
f1 (ppm)
3
3
.7
5
3
8
.0
2
5
3
.1
0
5
7
.0
6
1
2
1
.0
0
1
2
2
.3
4
1
2
2
.5
7
1
2
6
.9
8
1
2
7
.1
9
1
2
8
.5
2
1
2
9
.7
9
1
3
6
.2
0
1
3
7
.0
2
1
4
9
.4
0
1
4
9
.9
5
1
5
6
.9
1
1
5
7
.3
2
1
7
1
.7
4
1
7
2
.6
6
N-methyl-Néêëìíîïìðñéòéóôõðëìóôö÷ðñøùõíúð (44)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
f1 (ppm)
3
.0
0
2
.0
5
1
.0
0
0
.8
4
5
.9
1
2
.4
9
2
.5
0
2
.5
0
2
.5
0
2
.5
1
2
.9
0
4
.7
4
6
.9
9
7
.0
0
7
.0
0
7
.0
1
7
.0
4
7
.4
0
7
.4
0
7
.4
1
7
.4
2
7
.4
2
7
.4
3
7
.4
3
7
.4
4
7
.4
4
7
.4
4
7
.4
5
7
.4
5
7
.4
5
7
.4
6
7
.4
6
7
.4
7
N
O
N
43
N
O
S
44
S31
0102030405060708090100110120130140150160170180190200
f1 (ppm)
3
2
.9
2
3
6
.9
6
4
5
.8
8
5
0
.6
2
1
2
5
.7
3
1
2
6
.1
1
1
2
7
.1
4
1
2
8
.5
5
1
3
6
.1
8
1
3
9
.7
6
1
7
4
.0
5
N-(furan-2-ylmethyl)-Nûüýþß- ýüý (45)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
f1 (ppm)
3
.0
0
2
.0
8
0
.7
9
0
.8
5
4
.7
9
0
.9
2
2
.8
9
4
.5
4
6
.3
5
6
.4
2
6
.4
3
6
.4
3
6
.4
3
7
.4
0
7
.4
1
7
.4
1
7
.4
2
7
.4
2
7
.4
3
7
.4
3
7
.4
4
7
.4
4
7
.4
4
7
.4
4
7
.4
5
7
.4
5
7
.4
6
7
.4
7
7
.6
0
7
.6
0
7
.6
0
7
.6
1
N
O
S
44
N
O
O
45
S32
0102030405060708090100110120130140150160170180190200
f1 (ppm)
3
2
.9
8
3
7
.3
0
4
3
.7
6
4
8
.5
3
1
0
8
.5
6
1
0
8
.7
5
1
1
0
.4
9
1
2
7
.2
2
1
2
8
.5
3
1
2
9
.7
7
1
3
6
.2
1
1
4
2
.5
2
1
4
2
.8
0
1
5
0
.2
7
1
5
0
.9
0
1
7
1
.4
6
1
7
2
.2
2
N-(cyclohexylmethyl)-N	
		 (48)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
f1 (ppm)
3
.9
3
6
.9
8
3
.0
0
1
.7
2
1
.8
2
2
.9
9
1
.1
7
1
.2
0
1
.2
2
1
.5
5
1
.6
3
1
.6
6
1
.6
7
1
.7
0
2
.9
0
3
.2
3
7
.3
2
7
.3
3
7
.3
4
7
.3
5
7
.4
0
7
.4
1
7
.4
2
7
.4
2
7
.4
2
7
.4
3
7
.4
3
7
.4
4
7
.4
4
7
.4
4
N
O
O
45
N
O
48
S33
0102030405060708090100110120130140150160170180190200
f1 (ppm)
2
5
.9
0
2
5
.9
7
2
6
.0
5
2
6
.3
8
2
6
.5
4
2
6
.6
1
3
0
.5
7
3
0
.9
1
3
1
.0
6
3
3
.2
7
3
6
.0
0
3
6
.4
6
3
8
.1
9
3
8
.5
4
4
6
.3
5
5
3
.7
0
5
7
.7
1
1
2
6
.9
7
1
2
7
.1
9
1
2
8
.4
5
1
2
8
.6
6
1
2
9
.2
3
1
2
9
.3
8
1
3
1
.4
0
1
3
5
.1
1
1
3
7
.0
8
1
3
7
.2
4
1
6
7
.6
8
1
7
1
.7
7
1
7
2
.5
0
N-(2,2-dimethoxyethyl)-Nﬀﬁﬂﬃ  (49)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
f1 (ppm)
3
.0
0
6
.3
2
1
.8
0
1
.0
1
2
.0
3
2
.9
9
2
.9
6
3
.3
0
3
.4
4
4
.5
6
7
.3
6
7
.3
6
7
.3
7
7
.3
7
7
.3
7
7
.3
8
7
.4
3
7
.4
3
7
.4
4
N
O
48
N
O
OMe
OMe
49
S34
0102030405060708090100110120130140150160170180190200
f1 (ppm)
3
4
.4
7
3
9
.5
7
4
9
.9
7
5
3
.1
5
5
4
.8
2
1
0
3
.1
0
1
0
3
.5
0
1
2
7
.0
7
1
2
8
.4
8
1
2
9
.6
5
1
3
6
.5
3
1
7
1
.8
1
1
7
2
.6
0
N!"#$%&'!(!)'*+,+!N!.#/0&'"#$%1.23# (50)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
f1 (ppm)
3
.1
8
2
.1
2
4
.7
8
2
.0
9
2
.0
0
2
.8
7
4
.6
0
7
.2
2
7
.2
3
7
.2
4
7
.2
4
7
.2
5
7
.2
6
7
.2
7
7
.2
9
7
.3
1
7
.3
5
7
.3
7
7
.3
9
7
.3
9
7
.4
9
7
.5
0
7
.5
1
7
.5
1
7
.5
2
7
.5
3
N
O
OMe
OMe
49
F
N
O
50
S35
 
0102030405060708090100110120130140150160170180190200
f1 (ppm)
3
3
.5
9
3
7
.2
0
5
1
.0
9
5
5
.3
7
1
1
5
.5
3
1
1
5
.7
5
1
2
6
.7
4
1
2
7
.7
7
1
2
8
.3
5
1
2
8
.9
7
1
2
9
.3
7
1
3
2
.3
7
1
3
6
.7
0
1
3
7
.0
2
1
6
2
.2
6
1
6
4
.7
4
1
7
0
.6
8
N456789:4N,6-dimethylnicotinamide (51)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
f1 (ppm)
3
.4
3
2
.9
3
2
.0
0
3
.5
8
2
.0
9
0
.9
3
0
.8
6
2
.5
1
2
.9
0
4
.6
2
7
.2
9
7
.3
0
7
.3
0
7
.3
1
7
.3
2
7
.3
7
7
.3
8
7
.4
0
7
.7
5
7
.7
6
8
.5
3
F
N
O
50
N
N
O
51
S36
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f1 (ppm)
2
4
.4
9
3
3
.5
8
3
7
.0
8
5
1
.0
7
5
5
.2
8
1
2
2
.9
8
1
2
6
.6
1
1
2
7
.8
1
1
2
8
.3
2
1
2
8
.8
9
1
2
9
.0
1
1
2
9
.1
6
1
3
5
.2
4
1
3
5
.4
7
1
3
6
.2
4
1
3
6
.7
2
1
4
7
.2
7
1
4
7
.5
5
1
6
0
.0
5
1
6
9
.3
8
1
7
0
.1
2
N;<=>?@A-N;B=CD@AE@FG?H>=;I;JGF<KLGBHM= (52)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
f1 (ppm)
1
.5
8
1
.2
7
0
.8
5
1
.0
5
4
.6
2
0
.8
4
0
.8
6
0
.8
1
2
.9
3
2
.9
6
4
.6
0
4
.7
3
7
.2
6
7
.3
0
7
.3
3
7
.3
4
7
.3
7
8
.6
4
8
.6
7
8
.7
1
8
.7
3
8
.8
5
8
.8
9
N
N
O
51
N
N
N
O
52
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f1 (ppm)
3
3
.7
6
3
6
.6
4
5
1
.5
9
5
4
.7
5
1
2
7
.5
0
1
2
7
.8
2
1
2
7
.9
9
1
2
8
.3
6
1
2
8
.9
2
1
3
6
.4
4
1
3
6
.5
1
1
4
2
.6
5
1
4
2
.6
8
1
4
5
.4
0
1
4
5
.6
2
1
4
5
.6
6
1
4
9
.8
6
1
4
9
.9
6
1
6
6
.7
8
1
6
7
.0
5
NNOPQRSTNN-methyl-1H-pyrrole-2-carboxamide (53)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.512.0
f1 (ppm)
2
.8
0
2
.0
0
0
.9
5
0
.9
4
0
.9
4
4
.8
8
1
.0
0
3
.1
1
4
.7
5
6
.1
0
6
.1
0
6
.1
0
6
.1
1
6
.1
1
6
.1
2
6
.4
8
6
.9
0
6
.9
0
6
.9
0
7
.2
6
7
.2
6
7
.2
7
7
.2
8
7
.2
9
7
.3
4
7
.3
5
7
.3
5
7
.3
6
7
.3
6
7
.3
6
7
.3
6
7
.3
7
7
.3
8
1
1
.3
1
N
N
N
O
52
N
O
NH
53
S38
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f1 (ppm)
3
6
.2
0
5
2
.4
7
1
0
9
.7
8
1
1
2
.8
0
1
2
1
.4
6
1
2
4
.8
7
1
2
7
.5
0
1
2
8
.8
8
1
3
7
.2
6
1
6
3
.0
2
NUVWXYZ[UN-methylthiophene-2-carboxamide (54)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
f1 (ppm)
2
.8
1
2
.0
0
0
.9
4
2
.8
0
1
.9
2
0
.9
0
0
.8
3
3
.0
8
4
.7
3
7
.0
9
7
.1
0
7
.1
1
7
.1
2
7
.2
7
7
.2
9
7
.2
9
7
.3
1
7
.3
1
7
.3
6
7
.3
6
7
.3
8
7
.3
8
7
.3
9
7
.4
0
7
.4
0
7
.4
4
7
.4
4
7
.7
2
7
.7
3
7
.7
4
7
.7
4
N
O
NH
53
N
O
S
54
S39
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f1 (ppm)
3
5
.7
1
5
3
.5
4
1
2
6
.9
2
1
2
7
.6
9
1
2
8
.9
6
1
2
9
.2
3
1
3
6
.8
8
1
3
7
.9
4
1
6
4
.8
9
tert-butyl \]^\_`abcd\e`fgcdhiejakh^]^klk`fgcdhmin_ieif` (55)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
f1 (ppm)
1
0
.7
6
3
.0
0
1
.1
0
0
.8
6
1
.6
4
1
.8
9
4
.8
2
1
.3
9
2
.7
8
2
.8
3
2
.9
0
3
.6
7
3
.6
9
3
.8
4
3
.8
5
4
.5
2
7
.2
2
7
.2
4
7
.2
6
7
.3
0
7
.3
1
7
.3
3
N
O
S
54
N
O
H
N
Boc
55
S40
0102030405060708090100110120130140150160170180190200
f1 (ppm)
2
7
.9
4
3
3
.3
9
4
1
.6
3
5
0
.1
8
5
1
.1
9
7
7
.7
1
7
8
.0
0
1
2
6
.4
2
1
2
6
.7
3
1
2
6
.9
9
1
2
7
.2
5
1
2
8
.1
0
1
2
8
.4
0
1
3
7
.2
9
1
5
5
.4
2
1
6
8
.6
9
1
7
0
.4
8
NopqrstuoN-methyl-2-(2-oxopyrrolidin-1-yl)acetamide (56)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
f1 (ppm)
2
.0
0
1
.9
9
2
.9
6
2
.0
2
2
.0
2
2
.0
2
4
.7
4
1
.9
5
1
.9
7
1
.9
9
2
.1
9
2
.2
3
2
.2
5
2
.2
7
2
.8
2
2
.9
0
2
.9
2
3
.3
9
3
.4
1
3
.4
2
4
.1
2
4
.5
1
4
.5
7
5
.7
1
7
.2
2
7
.2
4
7
.2
7
7
.2
8
7
.3
2
7
.3
4
7
.3
6
N
O
H
N
Boc
55
N
O
N
O
56
S41
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f1 (ppm)
1
7
.2
6
2
9
.7
1
3
3
.5
8
4
3
.4
7
4
6
.9
5
5
0
.1
2
5
1
.5
4
5
4
.4
9
1
2
6
.3
5
1
2
6
.7
6
1
2
7
.2
8
1
2
8
.1
3
1
2
8
.4
0
1
6
7
.1
2
1
7
4
.0
1
N-methyl-Nvwxyz{|{}v~vyy}{| (57)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
f1 (ppm)
3
.0
0
2
.0
4
0
.9
3
4
.6
9
0
.8
7
1
.7
8
2
.8
9
4
.6
4
7
.3
7
7
.3
9
7
.3
9
7
.4
1
7
.4
4
7
.7
0
8
.5
0
8
.5
0
8
.5
1
8
.5
2
N
O
N
O
56
N
O
N
57
S42
0102030405060708090100110120130140150160170180190200
f1 (ppm)
3
3
.2
4
3
7
.2
2
4
8
.6
1
5
2
.9
3
1
2
3
.8
6
1
2
7
.0
8
1
2
8
.6
1
1
2
9
.9
6
1
3
2
.8
1
1
3
4
.5
6
1
3
5
.8
9
1
3
6
.1
5
1
4
8
.7
7
1
4
9
.2
4
1
4
9
.6
4
1
7
1
.9
0
N-butyl-NŁŁŁ (58)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
f1 (ppm)
3
.0
4
2
.1
0
2
.1
4
3
.0
0
1
.9
2
1
.8
6
2
.8
9
0
.8
5
1
.2
3
1
.5
1
1
.5
3
1
.5
4
2
.9
1
3
.3
2
7
.3
3
7
.3
4
7
.3
4
7
.3
5
7
.3
5
7
.3
5
7
.3
5
7
.3
6
7
.4
1
7
.4
1
7
.4
2
7
.4
2
7
.4
2
7
.4
3
7
.4
3
7
.4
3
7
.4
4
N
O
N
57
N
O
58
S43
0102030405060708090100110120130140150160170180190200
f1 (ppm)
1
3
.7
4
1
4
.0
3
1
9
.7
0
2
0
.2
3
2
9
.2
3
3
0
.4
9
3
2
.8
1
3
7
.5
6
4
7
.3
4
5
1
.1
8
1
2
6
.7
7
1
2
6
.9
7
1
2
8
.4
6
1
2
9
.3
6
1
3
7
.0
1
1
7
1
.3
9
1
7
2
.0
7
 (R ¡¢¢£¢¤¥¢¤¦§¥ ¨ (59)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
f1 (ppm)
3
.4
9
1
.0
0
2
.2
4
2
.0
7
0
.8
7
0
.8
9
1
0
.4
3
1
.3
7
1
.3
9
1
.4
0
1
.4
2
4
.2
6
4
.2
8
4
.2
9
4
.3
6
4
.3
8
4
.4
0
4
.4
1
4
.4
3
4
.4
5
4
.4
6
5
.0
1
5
.0
5
5
.0
8
5
.4
2
6
.5
5
7
.2
2
7
.2
4
7
.2
6
7
.2
6
7
.2
7
7
.2
7
7
.2
8
7
.2
9
7
.3
0
7
.3
1
7
.3
1
7
.3
2
7
.3
2
7
.3
3
7
.3
4
7
.3
5
7
.3
5
7
.3
6
7
.3
7
N
O
58
N
H
O
CbzHN
59
S44
0102030405060708090100110120130140150160170180190200
f1 (ppm)
1
8
.8
2
4
3
.6
5
5
0
.7
5
6
7
.1
8
1
2
7
.6
8
1
2
7
.7
7
1
2
8
.1
9
1
2
8
.3
8
1
2
8
.6
9
1
2
8
.8
5
1
3
6
.2
1
1
3
8
.0
0
1
5
6
.1
5
1
7
2
.2
8
©ª«¬­® (S¯°±²°±©ª«¬­®³´µ«¶¯°·°´ª¸¹­®°²°¶º¶»ª«¸³«°¼°­®¯½³¾©³´³¸ª (60)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
f1 (ppm)
6
.3
5
1
.0
3
2
.3
9
0
.8
9
2
.0
0
2
.1
3
0
.7
6
0
.7
8
9
.5
8
0
.9
4
0
.9
5
0
.9
6
0
.9
9
1
.5
4
1
.5
6
1
.5
8
1
.6
5
1
.6
6
1
.6
6
1
.6
7
1
.6
8
1
.6
8
1
.6
9
1
.7
0
1
.7
1
1
.7
2
1
.7
3
1
.7
3
1
.7
5
4
.2
4
4
.2
5
4
.3
8
4
.4
0
4
.4
2
4
.4
3
4
.4
5
4
.4
6
4
.4
8
4
.4
9
5
.0
5
5
.0
9
5
.1
2
5
.1
3
5
.2
9
5
.3
1
6
.5
2
7
.2
5
7
.2
7
7
.2
9
7
.2
9
7
.3
0
7
.3
0
7
.3
1
7
.3
2
7
.3
4
7
.3
5
7
.3
5
7
.3
6
7
.3
6
7
.3
7
7
.3
8
7
.3
8
N
H
O
CbzHN
59
N
H
O
NHCbz
60
S45
0102030405060708090100110120130140150160170180190200
f1 (ppm)
2
2
.1
1
2
3
.0
7
2
4
.8
4
4
1
.5
6
4
1
.9
1
4
3
.6
6
5
3
.7
6
6
7
.2
3
1
2
7
.6
6
1
2
7
.7
9
1
2
8
.1
7
1
2
8
.3
7
1
2
8
.6
8
1
2
8
.8
5
1
3
6
.2
3
1
3
8
.0
2
1
5
6
.4
3
1
7
2
.2
2
¿ÀÁÂÃÄ (SÅÆÇÈÆÇ¿ÀÁÂÃÄÉÊËÁÌÅÆÍÆÇÊÀÎÏÃÄÎÏËÌÅÆÈÆÌÐÌ¿ÑÎÉÁÆÒÆÃÄÅÓÉÔ¿ÉÊÉÎÀ (61)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
f1 (ppm)
5
.6
9
2
.4
2
3
.0
0
2
.2
5
0
.8
3
0
.8
1
1
0
.3
2
1
.9
5
1
.9
7
1
.9
9
2
.0
1
2
.0
3
2
.0
5
2
.0
7
2
.0
7
2
.0
8
2
.0
9
2
.1
0
2
.1
2
2
.1
4
2
.1
5
2
.4
7
2
.4
8
2
.5
0
2
.5
1
2
.5
2
2
.5
3
2
.5
4
2
.5
6
2
.5
8
4
.3
5
4
.3
6
4
.3
7
4
.3
9
4
.4
1
4
.4
2
4
.4
4
4
.4
6
4
.4
8
4
.4
9
5
.0
8
5
.1
1
5
.5
3
5
.5
5
6
.5
2
7
.2
4
7
.2
4
7
.2
4
7
.2
5
7
.2
6
7
.2
6
7
.2
7
7
.2
9
7
.2
9
7
.2
9
7
.3
1
7
.3
1
7
.3
2
7
.3
3
7
.3
4
7
.3
5
7
.3
5
7
.3
5
7
.3
5
7
.3
6
7
.3
7
N
H
O
NHCbz
60
N
H
O
NHCbz
S
61
S46
-20-100102030405060708090100110120130140150160170180190200210220
f1 (ppm)
1
5
.3
3
3
0
.2
9
3
1
.7
1
4
3
.7
7
5
4
.0
5
6
7
.3
1
1
2
7
.8
0
1
2
7
.8
6
1
2
8
.2
5
1
2
8
.4
2
1
2
8
.7
2
1
2
8
.9
3
1
3
7
.8
5
1
7
1
.0
2
(R)-NÕÖ×ØÙÚÛÕÜÕÝÚÞßàáÚÕÜÕâÝ×ØÚÛãä×åãæçÞ× (62)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
f1 (ppm)
1
.0
0
2
.1
3
1
.0
0
0
.9
9
1
.8
9
8
.0
4
3
.8
6
3
.8
9
4
.3
4
4
.3
6
4
.3
8
4
.3
9
4
.4
1
4
.4
3
4
.4
4
5
.0
1
5
.0
2
6
.6
7
7
.1
6
7
.1
8
7
.2
4
7
.2
5
7
.2
5
7
.2
6
7
.2
7
7
.2
7
7
.2
8
7
.2
8
7
.3
0
7
.3
2
7
.3
3
7
.3
4
7
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N-methyl-3-phenylpropan-1-amine (67)
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1-cyclohexyl-N-methylmethanamine (68)
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
f1 (ppm)
1
.9
0
2
.9
5
2
.0
0
4
.7
5
4
.2
8
0
.8
9
0
.9
0
0
.9
2
1
.1
6
1
.1
8
1
.2
0
1
.2
2
1
.2
3
1
.2
5
1
.4
4
1
.4
5
1
.4
6
1
.6
4
1
.6
7
1
.6
7
1
.6
9
1
.7
0
1
.7
1
1
.7
2
1
.7
4
2
.4
0
2
.4
2
N
H
67
N
H
68
S53
0102030405060708090100110120130140150160170180190200
f1 (ppm)
2
4
.9
2
2
5
.0
0
2
5
.5
3
2
5
.5
9
2
9
.6
3
2
9
.7
7
3
3
.1
5
3
4
.3
5
3
5
.4
9
4
4
.4
4
5
4
.2
5
Methyl 7789:;<=>?<@ABC8>:<=@DD-alaninate (69)
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Methyl EEFGHIJKLMJNOPQFLHJKNRL-leucinate (70)
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Methyl (R)-2-hydroxy-2-phenylacetate (72)
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Methyl (S)-2-(4-isobutylphenyl)propanoate (73).
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5. Chiral HPLC Spectra
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(S)-N´µ¶·¸¹º´»´¼¹½¾¿À¹´Á´Â¼¶·¹ºÂ¾¿ÂÃ·ÃÄÅ½¶ (63).
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(S)-NÆÇÈÉÊËÌÆÍÆÎËÏÐÑÒËÓÐÑÓÔÉÔÕÖÏÈ (64).
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(S)-Níîïðñòóíôíõöí÷øùîúûòóüýïðòóþüßùü-ð- ÷ï (66).
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